JP2014524419A - 放射標識された前立腺特異的膜抗原阻害剤 - Google Patents
放射標識された前立腺特異的膜抗原阻害剤 Download PDFInfo
- Publication number
- JP2014524419A JP2014524419A JP2014524142A JP2014524142A JP2014524419A JP 2014524419 A JP2014524419 A JP 2014524419A JP 2014524142 A JP2014524142 A JP 2014524142A JP 2014524142 A JP2014524142 A JP 2014524142A JP 2014524419 A JP2014524419 A JP 2014524419A
- Authority
- JP
- Japan
- Prior art keywords
- group
- alkylene
- compound
- formula
- heteroaryl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229940122569 Prostate-specific membrane antigen inhibitor Drugs 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract description 211
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 claims abstract description 65
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 claims abstract description 63
- 238000000034 method Methods 0.000 claims abstract description 34
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims abstract description 12
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 7
- -1 aryl alkylene Chemical group 0.000 claims description 114
- 125000005647 linker group Chemical group 0.000 claims description 65
- 125000001424 substituent group Chemical group 0.000 claims description 42
- 239000002738 chelating agent Substances 0.000 claims description 41
- 125000003118 aryl group Chemical group 0.000 claims description 38
- 150000003839 salts Chemical class 0.000 claims description 34
- 125000000217 alkyl group Chemical group 0.000 claims description 33
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 28
- 125000001072 heteroaryl group Chemical group 0.000 claims description 23
- 210000001519 tissue Anatomy 0.000 claims description 22
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 claims description 21
- 229910052739 hydrogen Inorganic materials 0.000 claims description 21
- 239000001257 hydrogen Substances 0.000 claims description 19
- 239000012453 solvate Substances 0.000 claims description 19
- 150000004696 coordination complex Chemical class 0.000 claims description 17
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 16
- 125000006832 (C1-C10) alkylene group Chemical group 0.000 claims description 14
- 125000002947 alkylene group Chemical group 0.000 claims description 14
- 229910052799 carbon Inorganic materials 0.000 claims description 14
- 150000002148 esters Chemical class 0.000 claims description 14
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 13
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 11
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims description 11
- 125000004103 aminoalkyl group Chemical group 0.000 claims description 10
- 125000001188 haloalkyl group Chemical group 0.000 claims description 10
- 229910052688 Gadolinium Inorganic materials 0.000 claims description 9
- 229910052801 chlorine Inorganic materials 0.000 claims description 9
- 229910052742 iron Inorganic materials 0.000 claims description 9
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 8
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 8
- 229910052794 bromium Inorganic materials 0.000 claims description 8
- 229910052731 fluorine Inorganic materials 0.000 claims description 8
- 229910052740 iodine Inorganic materials 0.000 claims description 8
- 150000002431 hydrogen Chemical group 0.000 claims description 7
- 229910052736 halogen Inorganic materials 0.000 claims description 6
- 150000002367 halogens Chemical class 0.000 claims description 6
- 239000003937 drug carrier Substances 0.000 claims description 4
- 210000002307 prostate Anatomy 0.000 claims description 4
- 125000000732 arylene group Chemical group 0.000 claims description 3
- 210000000952 spleen Anatomy 0.000 claims description 3
- 210000005084 renal tissue Anatomy 0.000 claims description 2
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims 6
- 125000005549 heteroarylene group Chemical group 0.000 claims 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims 1
- 201000010099 disease Diseases 0.000 abstract description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 12
- 229920001481 poly(stearyl methacrylate) Polymers 0.000 abstract description 5
- 230000000694 effects Effects 0.000 abstract description 4
- 239000003112 inhibitor Substances 0.000 abstract description 4
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 38
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 35
- 210000004027 cell Anatomy 0.000 description 29
- 229910052751 metal Inorganic materials 0.000 description 28
- 239000002184 metal Substances 0.000 description 28
- 239000000203 mixture Substances 0.000 description 28
- 230000027455 binding Effects 0.000 description 25
- 238000003786 synthesis reaction Methods 0.000 description 25
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 24
- WDLRUFUQRNWCPK-UHFFFAOYSA-N Tetraxetan Chemical group OC(=O)CN1CCN(CC(O)=O)CCN(CC(O)=O)CCN(CC(O)=O)CC1 WDLRUFUQRNWCPK-UHFFFAOYSA-N 0.000 description 24
- 230000015572 biosynthetic process Effects 0.000 description 22
- 125000004432 carbon atom Chemical group C* 0.000 description 21
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 20
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 20
- 206010060862 Prostate cancer Diseases 0.000 description 19
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 17
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 16
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 15
- 206010028980 Neoplasm Diseases 0.000 description 15
- 239000000243 solution Substances 0.000 description 15
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 14
- 239000002253 acid Substances 0.000 description 14
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 description 14
- 125000006850 spacer group Chemical group 0.000 description 14
- 238000003384 imaging method Methods 0.000 description 13
- 239000003446 ligand Substances 0.000 description 13
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 13
- 239000002904 solvent Substances 0.000 description 13
- 0 *CC(C(NC(CCC(O)=O)C(O)=O)O)N Chemical compound *CC(C(NC(CCC(O)=O)C(O)=O)O)N 0.000 description 12
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 12
- 239000010949 copper Substances 0.000 description 12
- 239000003814 drug Substances 0.000 description 12
- 229910021645 metal ion Inorganic materials 0.000 description 12
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 12
- 239000012217 radiopharmaceutical Substances 0.000 description 12
- 229940121896 radiopharmaceutical Drugs 0.000 description 12
- 230000002799 radiopharmaceutical effect Effects 0.000 description 12
- 125000002843 carboxylic acid group Chemical group 0.000 description 11
- 125000006239 protecting group Chemical group 0.000 description 11
- 230000002829 reductive effect Effects 0.000 description 11
- 229940024606 amino acid Drugs 0.000 description 10
- 238000004128 high performance liquid chromatography Methods 0.000 description 10
- 239000000543 intermediate Substances 0.000 description 10
- 150000007527 lewis bases Chemical class 0.000 description 10
- 239000011541 reaction mixture Substances 0.000 description 10
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical group CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 9
- 239000002879 Lewis base Substances 0.000 description 9
- 125000003545 alkoxy group Chemical group 0.000 description 9
- 235000001014 amino acid Nutrition 0.000 description 9
- 150000001413 amino acids Chemical class 0.000 description 9
- 125000004429 atom Chemical group 0.000 description 9
- 125000000623 heterocyclic group Chemical group 0.000 description 9
- 229910052738 indium Inorganic materials 0.000 description 9
- 230000003993 interaction Effects 0.000 description 9
- XEEYBQQBJWHFJM-UHFFFAOYSA-N iron Substances [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 9
- 229910052757 nitrogen Inorganic materials 0.000 description 9
- 229910052760 oxygen Inorganic materials 0.000 description 9
- 229940002612 prodrug Drugs 0.000 description 9
- 239000000651 prodrug Substances 0.000 description 9
- 210000004881 tumor cell Anatomy 0.000 description 9
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 8
- 239000004472 Lysine Substances 0.000 description 8
- 239000002872 contrast media Substances 0.000 description 8
- 235000018102 proteins Nutrition 0.000 description 8
- 102000004169 proteins and genes Human genes 0.000 description 8
- 108090000623 proteins and genes Proteins 0.000 description 8
- 229940124597 therapeutic agent Drugs 0.000 description 8
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Substances OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 8
- 125000000143 2-carboxyethyl group Chemical group [H]OC(=O)C([H])([H])C([H])([H])* 0.000 description 7
- 229910052765 Lutetium Inorganic materials 0.000 description 7
- 125000004450 alkenylene group Chemical group 0.000 description 7
- 239000007864 aqueous solution Substances 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 7
- 239000000460 chlorine Substances 0.000 description 7
- 125000004122 cyclic group Chemical group 0.000 description 7
- 125000005842 heteroatom Chemical group 0.000 description 7
- 210000003734 kidney Anatomy 0.000 description 7
- OHSVLFRHMCKCQY-UHFFFAOYSA-N lutetium atom Chemical compound [Lu] OHSVLFRHMCKCQY-UHFFFAOYSA-N 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- 230000002285 radioactive effect Effects 0.000 description 7
- 229920006395 saturated elastomer Polymers 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 6
- 125000003342 alkenyl group Chemical group 0.000 description 6
- 235000003704 aspartic acid Nutrition 0.000 description 6
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 6
- 201000011510 cancer Diseases 0.000 description 6
- 238000010511 deprotection reaction Methods 0.000 description 6
- 125000000524 functional group Chemical group 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 238000001959 radiotherapy Methods 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 230000008685 targeting Effects 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 5
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 5
- JFYDNJMLMNAWKO-UHFFFAOYSA-N 6-[(4-prop-2-ynoxyphenyl)methylamino]hexanoic acid Chemical compound OC(=O)CCCCCNCC1=CC=C(OCC#C)C=C1 JFYDNJMLMNAWKO-UHFFFAOYSA-N 0.000 description 5
- 229910021617 Indium monochloride Inorganic materials 0.000 description 5
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 5
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 5
- 230000021615 conjugation Effects 0.000 description 5
- 238000010828 elution Methods 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 230000014509 gene expression Effects 0.000 description 5
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 5
- APHGZSBLRQFRCA-UHFFFAOYSA-M indium(1+);chloride Chemical compound [In]Cl APHGZSBLRQFRCA-UHFFFAOYSA-M 0.000 description 5
- 125000002950 monocyclic group Chemical group 0.000 description 5
- 239000002245 particle Substances 0.000 description 5
- 230000002062 proliferating effect Effects 0.000 description 5
- 150000003384 small molecules Chemical class 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 241000894007 species Species 0.000 description 5
- 229910052717 sulfur Inorganic materials 0.000 description 5
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 description 4
- KBPLFHHGFOOTCA-UHFFFAOYSA-N 1-Octanol Chemical compound CCCCCCCCO KBPLFHHGFOOTCA-UHFFFAOYSA-N 0.000 description 4
- 125000004176 4-fluorobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1F)C([H])([H])* 0.000 description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 108090000369 Glutamate Carboxypeptidase II Proteins 0.000 description 4
- 102000003958 Glutamate Carboxypeptidase II Human genes 0.000 description 4
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 4
- 239000002202 Polyethylene glycol Substances 0.000 description 4
- 108010020346 Polyglutamic Acid Proteins 0.000 description 4
- 125000005907 alkyl ester group Chemical group 0.000 description 4
- 125000004419 alkynylene group Chemical group 0.000 description 4
- 150000001408 amides Chemical class 0.000 description 4
- 150000001412 amines Chemical class 0.000 description 4
- 125000003277 amino group Chemical group 0.000 description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 4
- 125000002619 bicyclic group Chemical group 0.000 description 4
- 150000001735 carboxylic acids Chemical class 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 230000000536 complexating effect Effects 0.000 description 4
- 229910052802 copper Inorganic materials 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 235000019441 ethanol Nutrition 0.000 description 4
- 125000000592 heterocycloalkyl group Chemical group 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 239000001301 oxygen Substances 0.000 description 4
- 229920001223 polyethylene glycol Polymers 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 125000004076 pyridyl group Chemical group 0.000 description 4
- UDNCSVCIWTVRIL-CXNSMIOJSA-N (2s)-2-[[(1s)-5-[6-[[1-[2-[bis(carboxymethyl)amino]-2-oxoethyl]imidazol-2-yl]methyl-[[4-[[1-[3-[[2-[4,7,10-tris(carboxymethyl)-1,4,7,10-tetrazacyclododec-1-yl]acetyl]amino]propyl]triazol-4-yl]methoxy]phenyl]methyl]amino]hexanoylamino]-1-carboxypentyl]carb Chemical compound C=1C=C(OCC=2N=NN(CCCNC(=O)CN3CCN(CC(O)=O)CCN(CC(O)=O)CCN(CC(O)=O)CC3)C=2)C=CC=1CN(CCCCCC(=O)NCCCC[C@H](NC(=O)N[C@@H](CCC(=O)O)C(O)=O)C(O)=O)CC1=NC=CN1CC(=O)N(CC(O)=O)CC(O)=O UDNCSVCIWTVRIL-CXNSMIOJSA-N 0.000 description 3
- IRSVWQMQTFXJST-SDHOMARFSA-N (2s)-2-[[(1s)-5-[[(2s)-2-amino-6-[[2-[4,7,10-tris(carboxymethyl)-1,4,7,10-tetrazacyclododec-1-yl]acetyl]amino]hexanoyl]amino]-1-carboxypentyl]carbamoylamino]pentanedioic acid Chemical compound OC(=O)CC[C@@H](C(O)=O)NC(=O)N[C@H](C(O)=O)CCCCNC(=O)[C@@H](N)CCCCNC(=O)CN1CCN(CC(O)=O)CCN(CC(O)=O)CCN(CC(O)=O)CC1 IRSVWQMQTFXJST-SDHOMARFSA-N 0.000 description 3
- IQPLKPZWRJSPBB-UHFFFAOYSA-N 6-[[1-[2-[(2-methylpropan-2-yl)oxy]-2-oxoethyl]imidazol-2-yl]methyl-[(4-prop-2-ynoxyphenyl)methyl]amino]hexanoic acid Chemical compound CC(C)(C)OC(=O)CN1C=CN=C1CN(CCCCCC(O)=O)CC1=CC=C(OCC#C)C=C1 IQPLKPZWRJSPBB-UHFFFAOYSA-N 0.000 description 3
- OLHWLPCYOVZCTO-UHFFFAOYSA-N 6-[[1-[2-[bis[2-[(2-methylpropan-2-yl)oxy]-2-oxoethyl]amino]-2-oxoethyl]imidazol-2-yl]methyl-[(4-prop-2-ynoxyphenyl)methyl]amino]hexanoic acid Chemical compound CC(C)(C)OC(=O)CN(CC(=O)OC(C)(C)C)C(=O)CN1C=CN=C1CN(CCCCCC(O)=O)CC1=CC=C(OCC#C)C=C1 OLHWLPCYOVZCTO-UHFFFAOYSA-N 0.000 description 3
- SLXKOJJOQWFEFD-UHFFFAOYSA-N 6-aminohexanoic acid Chemical group NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 3
- 239000005695 Ammonium acetate Substances 0.000 description 3
- MWDZNOMWWXRZDU-UHFFFAOYSA-N C(CCCCCCC(CCCC(CCC(=O)O)C(=O)O)C(=O)O)CCCCCCNNNNNN Chemical compound C(CCCCCCC(CCCC(CCC(=O)O)C(=O)O)C(=O)O)CCCCCCNNNNNN MWDZNOMWWXRZDU-UHFFFAOYSA-N 0.000 description 3
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 3
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 3
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 3
- DSIPJYFJXDMVGG-MPKYGIEOSA-N OC1=CC=CC=C1\C=N/CCNCCNCC\N=C/C1=CC=CC=C1O Chemical compound OC1=CC=CC=C1\C=N/CCNCCNCC\N=C/C1=CC=CC=C1O DSIPJYFJXDMVGG-MPKYGIEOSA-N 0.000 description 3
- 241000288906 Primates Species 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 230000002378 acidificating effect Effects 0.000 description 3
- 150000001298 alcohols Chemical class 0.000 description 3
- 150000001345 alkine derivatives Chemical class 0.000 description 3
- 125000000304 alkynyl group Chemical group 0.000 description 3
- 125000000539 amino acid group Chemical group 0.000 description 3
- 229940043376 ammonium acetate Drugs 0.000 description 3
- 235000019257 ammonium acetate Nutrition 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 3
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
- 150000001721 carbon Chemical group 0.000 description 3
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 3
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 3
- 230000001268 conjugating effect Effects 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 235000014113 dietary fatty acids Nutrition 0.000 description 3
- LIRASKOCEBDWLD-CXNSMIOJSA-N ditert-butyl (2s)-2-[[(2s)-6-[6-[[1-[2-[bis[2-[(2-methylpropan-2-yl)oxy]-2-oxoethyl]amino]-2-oxoethyl]imidazol-2-yl]methyl-[(4-prop-2-ynoxyphenyl)methyl]amino]hexanoylamino]-1-[(2-methylpropan-2-yl)oxy]-1-oxohexan-2-yl]carbamoylamino]pentanedioate Chemical compound C=1C=C(OCC#C)C=CC=1CN(CCCCCC(=O)NCCCC[C@H](NC(=O)N[C@@H](CCC(=O)OC(C)(C)C)C(=O)OC(C)(C)C)C(=O)OC(C)(C)C)CC1=NC=CN1CC(=O)N(CC(=O)OC(C)(C)C)CC(=O)OC(C)(C)C LIRASKOCEBDWLD-CXNSMIOJSA-N 0.000 description 3
- 239000000194 fatty acid Substances 0.000 description 3
- 229930195729 fatty acid Natural products 0.000 description 3
- 229920000370 gamma-poly(glutamate) polymer Polymers 0.000 description 3
- 239000004220 glutamic acid Substances 0.000 description 3
- 125000002883 imidazolyl group Chemical group 0.000 description 3
- 238000007913 intrathecal administration Methods 0.000 description 3
- 150000002500 ions Chemical class 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- 206010061289 metastatic neoplasm Diseases 0.000 description 3
- 150000004702 methyl esters Chemical class 0.000 description 3
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 125000002757 morpholinyl group Chemical group 0.000 description 3
- 125000001624 naphthyl group Chemical group 0.000 description 3
- 125000002971 oxazolyl group Chemical group 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 230000005855 radiation Effects 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 125000004213 tert-butoxy group Chemical group [H]C([H])([H])C(O*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 3
- 229960003986 tuaminoheptane Drugs 0.000 description 3
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 2
- GRUVVLWKPGIYEG-UHFFFAOYSA-N 2-[2-[carboxymethyl-[(2-hydroxyphenyl)methyl]amino]ethyl-[(2-hydroxyphenyl)methyl]amino]acetic acid Chemical compound C=1C=CC=C(O)C=1CN(CC(=O)O)CCN(CC(O)=O)CC1=CC=CC=C1O GRUVVLWKPGIYEG-UHFFFAOYSA-N 0.000 description 2
- HDTPONPWSVZVGA-UHFFFAOYSA-N 2-[4,10-bis(carboxymethyl)-7-[2-(2,5-dioxopyrrol-1-yl)oxy-2-oxoethyl]-1,4,7,10-tetrazacyclododec-1-yl]acetic acid Chemical compound C1CN(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CCN1CC(=O)ON1C(=O)C=CC1=O HDTPONPWSVZVGA-UHFFFAOYSA-N 0.000 description 2
- JHALWMSZGCVVEM-UHFFFAOYSA-N 2-[4,7-bis(carboxymethyl)-1,4,7-triazonan-1-yl]acetic acid Chemical compound OC(=O)CN1CCN(CC(O)=O)CCN(CC(O)=O)CC1 JHALWMSZGCVVEM-UHFFFAOYSA-N 0.000 description 2
- STNZNCWQNMGRIM-UHFFFAOYSA-N 2-benzyl-1,4,7,10-tetrakis-(4-methylphenyl)sulfonyl-1,4,7,10-tetrazacyclododecane Chemical compound C1=CC(C)=CC=C1S(=O)(=O)N1CCN(S(=O)(=O)C=2C=CC(C)=CC=2)CC(CC=2C=CC=CC=2)N(S(=O)(=O)C=2C=CC(C)=CC=2)CCN(S(=O)(=O)C=2C=CC(C)=CC=2)CC1 STNZNCWQNMGRIM-UHFFFAOYSA-N 0.000 description 2
- XNMQEEKYCVKGBD-UHFFFAOYSA-N 2-butyne Chemical compound CC#CC XNMQEEKYCVKGBD-UHFFFAOYSA-N 0.000 description 2
- NKTDTMONXHODTI-UHFFFAOYSA-N 2-pentyne Chemical compound CCC#CC NKTDTMONXHODTI-UHFFFAOYSA-N 0.000 description 2
- 125000004042 4-aminobutyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])N([H])[H] 0.000 description 2
- 125000001572 5'-adenylyl group Chemical group C=12N=C([H])N=C(N([H])[H])C=1N=C([H])N2[C@@]1([H])[C@@](O[H])([H])[C@@](O[H])([H])[C@](C(OP(=O)(O[H])[*])([H])[H])([H])O1 0.000 description 2
- OPVPGKGADVGKTG-BQBZGAKWSA-N Ac-Asp-Glu Chemical compound CC(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(O)=O)CCC(O)=O OPVPGKGADVGKTG-BQBZGAKWSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- UHXQAMAUWFYAPV-NAZWXXJZSA-N Cc1ccc(C2N(CC/N=C\c3ccccc3O)CCN2CC/N=C\c(cccc2)c2O)c(O)c1 Chemical compound Cc1ccc(C2N(CC/N=C\c3ccccc3O)CCN2CC/N=C\c(cccc2)c2O)c(O)c1 UHXQAMAUWFYAPV-NAZWXXJZSA-N 0.000 description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
- 241000283086 Equidae Species 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-L L-tartrate(2-) Chemical compound [O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O FEWJPZIEWOKRBE-JCYAYHJZSA-L 0.000 description 2
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- 241000286209 Phasianidae Species 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 241000282887 Suidae Species 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- GKLVYJBZJHMRIY-OUBTZVSYSA-N Technetium-99 Chemical compound [99Tc] GKLVYJBZJHMRIY-OUBTZVSYSA-N 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 2
- 150000001336 alkenes Chemical class 0.000 description 2
- 125000001118 alkylidene group Chemical group 0.000 description 2
- 125000003710 aryl alkyl group Chemical group 0.000 description 2
- 229940009098 aspartate Drugs 0.000 description 2
- 125000005334 azaindolyl group Chemical group N1N=C(C2=CC=CC=C12)* 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 2
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 2
- 125000005874 benzothiadiazolyl group Chemical group 0.000 description 2
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 2
- 125000003354 benzotriazolyl group Chemical group N1N=NC2=C1C=CC=C2* 0.000 description 2
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- GZUXJHMPEANEGY-UHFFFAOYSA-N bromomethane Chemical compound BrC GZUXJHMPEANEGY-UHFFFAOYSA-N 0.000 description 2
- KDKYADYSIPSCCQ-UHFFFAOYSA-N but-1-yne Chemical compound CCC#C KDKYADYSIPSCCQ-UHFFFAOYSA-N 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 150000007942 carboxylates Chemical class 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 239000013522 chelant Substances 0.000 description 2
- 125000003636 chemical group Chemical group 0.000 description 2
- 230000009918 complex formation Effects 0.000 description 2
- 238000010668 complexation reaction Methods 0.000 description 2
- 125000004093 cyano group Chemical group *C#N 0.000 description 2
- 125000006165 cyclic alkyl group Chemical group 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- UYEGWXZBOLEEMA-COCZKOEFSA-N ditert-butyl (2s)-2-[[(2s)-6-[6-[[4-[[1-(3-aminopropyl)triazol-4-yl]methoxy]phenyl]methyl-[[1-[2-[(2-methylpropan-2-yl)oxy]-2-oxoethyl]imidazol-2-yl]methyl]amino]hexanoylamino]-1-[(2-methylpropan-2-yl)oxy]-1-oxohexan-2-yl]carbamoylamino]pentanedioate Chemical compound C=1C=C(OCC=2N=NN(CCCN)C=2)C=CC=1CN(CCCCCC(=O)NCCCC[C@H](NC(=O)N[C@@H](CCC(=O)OC(C)(C)C)C(=O)OC(C)(C)C)C(=O)OC(C)(C)C)CC1=NC=CN1CC(=O)OC(C)(C)C UYEGWXZBOLEEMA-COCZKOEFSA-N 0.000 description 2
- GZVBWNZLDNNCCQ-MVRBIKRMSA-N ditert-butyl (2s)-2-[[(2s)-6-[6-[[4-[[1-(3-aminopropyl)triazol-4-yl]methoxy]phenyl]methyl-[[1-[2-[bis[2-[(2-methylpropan-2-yl)oxy]-2-oxoethyl]amino]-2-oxoethyl]imidazol-2-yl]methyl]amino]hexanoylamino]-1-[(2-methylpropan-2-yl)oxy]-1-oxohexan-2-yl]carbamoy Chemical compound C=1C=C(OCC=2N=NN(CCCN)C=2)C=CC=1CN(CCCCCC(=O)NCCCC[C@H](NC(=O)N[C@@H](CCC(=O)OC(C)(C)C)C(=O)OC(C)(C)C)C(=O)OC(C)(C)C)CC1=NC=CN1CC(=O)N(CC(=O)OC(C)(C)C)CC(=O)OC(C)(C)C GZVBWNZLDNNCCQ-MVRBIKRMSA-N 0.000 description 2
- VCGJAMGYAGXILX-SVWSIEHRSA-N ditert-butyl (2s)-2-[[(2s)-6-[[(2s)-2-amino-6-[[2-[4,7,10-tris[2-[(2-methylpropan-2-yl)oxy]-2-oxoethyl]-1,4,7,10-tetrazacyclododec-1-yl]acetyl]amino]hexanoyl]amino]-1-[(2-methylpropan-2-yl)oxy]-1-oxohexan-2-yl]carbamoylamino]pentanedioate Chemical compound CC(C)(C)OC(=O)CC[C@@H](C(=O)OC(C)(C)C)NC(=O)N[C@H](C(=O)OC(C)(C)C)CCCCNC(=O)[C@@H](N)CCCCNC(=O)CN1CCN(CC(=O)OC(C)(C)C)CCN(CC(=O)OC(C)(C)C)CCN(CC(=O)OC(C)(C)C)CC1 VCGJAMGYAGXILX-SVWSIEHRSA-N 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 125000005677 ethinylene group Chemical group [*:2]C#C[*:1] 0.000 description 2
- 125000004494 ethyl ester group Chemical group 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- MMXKVMNBHPAILY-UHFFFAOYSA-N ethyl laurate Chemical compound CCCCCCCCCCCC(=O)OCC MMXKVMNBHPAILY-UHFFFAOYSA-N 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 125000002541 furyl group Chemical group 0.000 description 2
- 229930195712 glutamate Natural products 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-L glutamate group Chemical group N[C@@H](CCC(=O)[O-])C(=O)[O-] WHUUTDBJXJRKMK-VKHMYHEASA-L 0.000 description 2
- 125000005843 halogen group Chemical group 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 125000002632 imidazolidinyl group Chemical group 0.000 description 2
- 125000002636 imidazolinyl group Chemical group 0.000 description 2
- 150000003949 imides Chemical class 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 2
- APFVFJFRJDLVQX-UHFFFAOYSA-N indium atom Chemical compound [In] APFVFJFRJDLVQX-UHFFFAOYSA-N 0.000 description 2
- 125000001041 indolyl group Chemical group 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 238000001361 intraarterial administration Methods 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 125000000842 isoxazolyl group Chemical group 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 230000001394 metastastic effect Effects 0.000 description 2
- 125000001434 methanylylidene group Chemical group [H]C#[*] 0.000 description 2
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 210000000653 nervous system Anatomy 0.000 description 2
- 150000002825 nitriles Chemical class 0.000 description 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 2
- 125000004433 nitrogen atom Chemical group N* 0.000 description 2
- 125000005151 nonafluorobutanesulfonyl group Chemical group FC(C(C(S(=O)(=O)*)(F)F)(F)F)(C(F)(F)F)F 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 235000021317 phosphate Nutrition 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 108010064470 polyaspartate Proteins 0.000 description 2
- 229920005862 polyol Polymers 0.000 description 2
- 150000003077 polyols Chemical class 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 2
- 125000003373 pyrazinyl group Chemical group 0.000 description 2
- 125000003226 pyrazolyl group Chemical group 0.000 description 2
- 125000002098 pyridazinyl group Chemical group 0.000 description 2
- 125000006085 pyrrolopyridyl group Chemical group 0.000 description 2
- 125000000168 pyrrolyl group Chemical group 0.000 description 2
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 2
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 2
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 2
- 229940051022 radioimmunoconjugate Drugs 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 230000009870 specific binding Effects 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 125000003107 substituted aryl group Chemical group 0.000 description 2
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 2
- 239000011593 sulfur Substances 0.000 description 2
- 229940095064 tartrate Drugs 0.000 description 2
- 229940056501 technetium 99m Drugs 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 150000000000 tetracarboxylic acids Chemical class 0.000 description 2
- 125000000147 tetrahydroquinolinyl group Chemical group N1(CCCC2=CC=CC=C12)* 0.000 description 2
- 125000003831 tetrazolyl group Chemical group 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 125000000335 thiazolyl group Chemical group 0.000 description 2
- 125000001544 thienyl group Chemical group 0.000 description 2
- 150000003573 thiols Chemical class 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 125000001425 triazolyl group Chemical group 0.000 description 2
- 125000001889 triflyl group Chemical group FC(F)(F)S(*)(=O)=O 0.000 description 2
- ILBBUDAYWABEFI-FAIXQHPJSA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-6-[[2-[4,7,10-tris[2-[(2-methylpropan-2-yl)oxy]-2-oxoethyl]-1,4,7,10-tetrazacyclododec-1-yl]acetyl]amino]hexanoic acid Chemical compound C1CN(CC(=O)OC(C)(C)C)CCN(CC(=O)OC(C)(C)C)CCN(CC(=O)OC(C)(C)C)CCN1CC(=O)NCCCC[C@@H](C(O)=O)NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21 ILBBUDAYWABEFI-FAIXQHPJSA-N 0.000 description 1
- 125000006648 (C1-C8) haloalkyl group Chemical group 0.000 description 1
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 description 1
- 125000006708 (C5-C14) heteroaryl group Chemical group 0.000 description 1
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 1
- 125000001399 1,2,3-triazolyl group Chemical group N1N=NC(=C1)* 0.000 description 1
- 125000001376 1,2,4-triazolyl group Chemical group N1N=C(N=C1)* 0.000 description 1
- CGHIBGNXEGJPQZ-UHFFFAOYSA-N 1-hexyne Chemical compound CCCCC#C CGHIBGNXEGJPQZ-UHFFFAOYSA-N 0.000 description 1
- IBXNCJKFFQIKKY-UHFFFAOYSA-N 1-pentyne Chemical compound CCCC#C IBXNCJKFFQIKKY-UHFFFAOYSA-N 0.000 description 1
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- ZEVWQFWTGHFIDH-UHFFFAOYSA-N 1h-imidazole-4,5-dicarboxylic acid Chemical compound OC(=O)C=1N=CNC=1C(O)=O ZEVWQFWTGHFIDH-UHFFFAOYSA-N 0.000 description 1
- MFJGKANGMGVDQC-UHFFFAOYSA-N 2-(2-methylprop-1-enyl)pyridine Chemical group CC(C)=CC1=CC=CC=N1 MFJGKANGMGVDQC-UHFFFAOYSA-N 0.000 description 1
- ISEYJGQFXSTPMQ-UHFFFAOYSA-N 2-(phosphonomethyl)pentanedioic acid Chemical compound OC(=O)CCC(C(O)=O)CP(O)(O)=O ISEYJGQFXSTPMQ-UHFFFAOYSA-N 0.000 description 1
- 125000000022 2-aminoethyl group Chemical group [H]C([*])([H])C([H])([H])N([H])[H] 0.000 description 1
- UPHOPMSGKZNELG-UHFFFAOYSA-N 2-hydroxynaphthalene-1-carboxylic acid Chemical compound C1=CC=C2C(C(=O)O)=C(O)C=CC2=C1 UPHOPMSGKZNELG-UHFFFAOYSA-N 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- OYBOVXXFJYJYPC-UHFFFAOYSA-N 3-azidopropan-1-amine Chemical compound NCCCN=[N+]=[N-] OYBOVXXFJYJYPC-UHFFFAOYSA-N 0.000 description 1
- ALKYHXVLJMQRLQ-UHFFFAOYSA-M 3-carboxynaphthalen-2-olate Chemical compound C1=CC=C2C=C(C([O-])=O)C(O)=CC2=C1 ALKYHXVLJMQRLQ-UHFFFAOYSA-M 0.000 description 1
- DQQNMIPXXNPGCV-UHFFFAOYSA-N 3-hexyne Chemical compound CCC#CCC DQQNMIPXXNPGCV-UHFFFAOYSA-N 0.000 description 1
- POLIXZIAIMAECK-UHFFFAOYSA-N 4-[2-(2,6-dioxomorpholin-4-yl)ethyl]morpholine-2,6-dione Chemical compound C1C(=O)OC(=O)CN1CCN1CC(=O)OC(=O)C1 POLIXZIAIMAECK-UHFFFAOYSA-N 0.000 description 1
- PUINVXGYZJXMMX-UHFFFAOYSA-N 4-isocyanatobenzaldehyde Chemical compound O=CC1=CC=C(N=C=O)C=C1 PUINVXGYZJXMMX-UHFFFAOYSA-N 0.000 description 1
- GSSBOYWRKTVVQX-UHFFFAOYSA-N 4-prop-2-ynoxybenzaldehyde Chemical compound O=CC1=CC=C(OCC#C)C=C1 GSSBOYWRKTVVQX-UHFFFAOYSA-N 0.000 description 1
- BNDRECGBDISUAI-UHFFFAOYSA-N 6-(2-phenylethenyl)cyclohexa-2,4-diene-1,1-disulfonic acid Chemical compound OS(=O)(=O)C1(S(O)(=O)=O)C=CC=CC1C=CC1=CC=CC=C1 BNDRECGBDISUAI-UHFFFAOYSA-N 0.000 description 1
- BDDLHHRCDSJVKV-UHFFFAOYSA-N 7028-40-2 Chemical compound CC(O)=O.CC(O)=O.CC(O)=O.CC(O)=O BDDLHHRCDSJVKV-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 208000006386 Bone Resorption Diseases 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
- 125000004649 C2-C8 alkynyl group Chemical group 0.000 description 1
- RFKZCADWMMFLEW-GJZGRUSLSA-N CC(C)(C)OC(=O)CC[C@@H](C(=O)OC(C)(C)C)NC(=O)N[C@H](CCC(=O)O)OOC(C)(C)C Chemical compound CC(C)(C)OC(=O)CC[C@@H](C(=O)OC(C)(C)C)NC(=O)N[C@H](CCC(=O)O)OOC(C)(C)C RFKZCADWMMFLEW-GJZGRUSLSA-N 0.000 description 1
- DKPIWFPLTPPVBV-UHFFFAOYSA-N CC(C)Cc1ncc[n]1CC(O)=O Chemical compound CC(C)Cc1ncc[n]1CC(O)=O DKPIWFPLTPPVBV-UHFFFAOYSA-N 0.000 description 1
- DBNBIPTYJBQFPZ-UHFFFAOYSA-N CC(NC(CC(O)=O)C(O)=O)OC Chemical compound CC(NC(CC(O)=O)C(O)=O)OC DBNBIPTYJBQFPZ-UHFFFAOYSA-N 0.000 description 1
- HSXRCEVTMOWCFI-UHFFFAOYSA-N CC1N(CC(O)=O)CCN(CC(O)=O)CCN(CC(O)=O)CCN(CC(O)=O)C1 Chemical compound CC1N(CC(O)=O)CCN(CC(O)=O)CCN(CC(O)=O)CCN(CC(O)=O)C1 HSXRCEVTMOWCFI-UHFFFAOYSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 150000008574 D-amino acids Chemical class 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- 102000004860 Dipeptidases Human genes 0.000 description 1
- 108090001081 Dipeptidases Proteins 0.000 description 1
- 108010016626 Dipeptides Proteins 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- 108010091443 Exopeptidases Proteins 0.000 description 1
- 102000018389 Exopeptidases Human genes 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 150000000921 Gadolinium Chemical class 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 150000008575 L-amino acids Chemical class 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 239000002841 Lewis acid Substances 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 150000001169 Lutetium Chemical class 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 108010006035 Metalloproteases Proteins 0.000 description 1
- 102000005741 Metalloproteases Human genes 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 1
- QPCDCPDFJACHGM-UHFFFAOYSA-N N,N-bis{2-[bis(carboxymethyl)amino]ethyl}glycine Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CC(O)=O QPCDCPDFJACHGM-UHFFFAOYSA-N 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- OTCCIMWXFLJLIA-UHFFFAOYSA-N N-acetyl-DL-aspartic acid Natural products CC(=O)NC(C(O)=O)CC(O)=O OTCCIMWXFLJLIA-UHFFFAOYSA-N 0.000 description 1
- OTCCIMWXFLJLIA-BYPYZUCNSA-N N-acetyl-L-aspartic acid Chemical compound CC(=O)N[C@H](C(O)=O)CC(O)=O OTCCIMWXFLJLIA-BYPYZUCNSA-N 0.000 description 1
- 150000001204 N-oxides Chemical class 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 241000283903 Ovis aries Species 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium on carbon Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 229920002732 Polyanhydride Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- QOSMNYMQXIVWKY-UHFFFAOYSA-N Propyl levulinate Chemical compound CCCOC(=O)CCC(C)=O QOSMNYMQXIVWKY-UHFFFAOYSA-N 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 235000019485 Safflower oil Nutrition 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 229920002253 Tannate Polymers 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-M Thiocyanate anion Chemical compound [S-]C#N ZMZDMBWJUHKJPS-UHFFFAOYSA-M 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 229910052770 Uranium Inorganic materials 0.000 description 1
- 150000001225 Ytterbium Chemical class 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical group [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 150000001241 acetals Chemical class 0.000 description 1
- 125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 125000002723 alicyclic group Chemical group 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001447 alkali salts Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000004703 alkoxides Chemical group 0.000 description 1
- 125000005262 alkoxyamine group Chemical group 0.000 description 1
- 125000004448 alkyl carbonyl group Chemical group 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- 150000001371 alpha-amino acids Chemical class 0.000 description 1
- 235000008206 alpha-amino acids Nutrition 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 150000001409 amidines Chemical class 0.000 description 1
- 229960002684 aminocaproic acid Drugs 0.000 description 1
- 125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 description 1
- VZTDIZULWFCMLS-UHFFFAOYSA-N ammonium formate Chemical compound [NH4+].[O-]C=O VZTDIZULWFCMLS-UHFFFAOYSA-N 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 239000003098 androgen Substances 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 125000002178 anthracenyl group Chemical group C1(=CC=CC2=CC3=CC=CC=C3C=C12)* 0.000 description 1
- 239000012062 aqueous buffer Substances 0.000 description 1
- 125000002102 aryl alkyloxo group Chemical group 0.000 description 1
- 125000004104 aryloxy group Chemical group 0.000 description 1
- 239000012911 assay medium Substances 0.000 description 1
- 238000011914 asymmetric synthesis Methods 0.000 description 1
- 125000002393 azetidinyl group Chemical group 0.000 description 1
- 150000001540 azides Chemical class 0.000 description 1
- 125000004069 aziridinyl group Chemical group 0.000 description 1
- 125000003828 azulenyl group Chemical group 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 125000004622 benzoxazinyl group Chemical group O1NC(=CC2=C1C=CC=C2)* 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 150000001576 beta-amino acids Chemical class 0.000 description 1
- JSMRMEYFZHIPJV-UHFFFAOYSA-N bicyclo[2.1.1]hexane Chemical compound C1C2CC1CC2 JSMRMEYFZHIPJV-UHFFFAOYSA-N 0.000 description 1
- 125000006267 biphenyl group Chemical group 0.000 description 1
- 125000002529 biphenylenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3C12)* 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000008081 blood perfusion Effects 0.000 description 1
- 230000024279 bone resorption Effects 0.000 description 1
- 229910052796 boron Inorganic materials 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 235000013877 carbamide Nutrition 0.000 description 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 1
- 125000001951 carbamoylamino group Chemical group C(N)(=O)N* 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 125000005588 carbonic acid salt group Chemical group 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 238000009903 catalytic hydrogenation reaction Methods 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 150000004697 chelate complex Chemical class 0.000 description 1
- 235000013330 chicken meat Nutrition 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 239000012230 colorless oil Substances 0.000 description 1
- 238000012875 competitive assay Methods 0.000 description 1
- 230000009137 competitive binding Effects 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 229940126214 compound 3 Drugs 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 229940039231 contrast media Drugs 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 150000003983 crown ethers Chemical class 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- XLJMAIOERFSOGZ-UHFFFAOYSA-M cyanate Chemical compound [O-]C#N XLJMAIOERFSOGZ-UHFFFAOYSA-M 0.000 description 1
- 150000004292 cyclic ethers Chemical class 0.000 description 1
- 125000000000 cycloalkoxy group Chemical group 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000003678 cyclohexadienyl group Chemical group C1(=CC=CCC1)* 0.000 description 1
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 125000004855 decalinyl group Chemical group C1(CCCC2CCCCC12)* 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- 238000002059 diagnostic imaging Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- QCIDPVZTCWQMOH-UHFFFAOYSA-N diazonio-[3-[[2-[4,7,10-tris[2-[(2-methylpropan-2-yl)oxy]-2-oxoethyl]-1,4,7,10-tetrazacyclododec-1-yl]acetyl]amino]propyl]azanide Chemical compound CC(C)(C)OC(=O)CN1CCN(CC(=O)NCCC[N-][N+]#N)CCN(CC(=O)OC(C)(C)C)CCN(CC(=O)OC(C)(C)C)CC1 QCIDPVZTCWQMOH-UHFFFAOYSA-N 0.000 description 1
- ACYGYJFTZSAZKR-UHFFFAOYSA-J dicalcium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Ca+2].[Ca+2].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O ACYGYJFTZSAZKR-UHFFFAOYSA-J 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 125000005433 dihydrobenzodioxinyl group Chemical group O1C(COC2=C1C=CC=C2)* 0.000 description 1
- 125000000723 dihydrobenzofuranyl group Chemical group O1C(CC2=C1C=CC=C2)* 0.000 description 1
- 125000001070 dihydroindolyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 1
- 125000004925 dihydropyridyl group Chemical group N1(CC=CC=C1)* 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- SPCNPOWOBZQWJK-UHFFFAOYSA-N dimethoxy-(2-propan-2-ylsulfanylethylsulfanyl)-sulfanylidene-$l^{5}-phosphane Chemical compound COP(=S)(OC)SCCSC(C)C SPCNPOWOBZQWJK-UHFFFAOYSA-N 0.000 description 1
- 239000001177 diphosphate Substances 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
- 235000011180 diphosphates Nutrition 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- KPUWHANPEXNPJT-UHFFFAOYSA-N disiloxane Chemical class [SiH3]O[SiH3] KPUWHANPEXNPJT-UHFFFAOYSA-N 0.000 description 1
- XULCLDSGJMZTHS-YDAXCOIMSA-N ditert-butyl (2s)-2-[[(2s)-1-[(2-methylpropan-2-yl)oxy]-6-[6-[[1-[2-[(2-methylpropan-2-yl)oxy]-2-oxoethyl]imidazol-2-yl]methyl-[(4-prop-2-ynoxyphenyl)methyl]amino]hexanoylamino]-1-oxohexan-2-yl]carbamoylamino]pentanedioate Chemical compound C=1C=C(OCC#C)C=CC=1CN(CCCCCC(=O)NCCCC[C@H](NC(=O)N[C@@H](CCC(=O)OC(C)(C)C)C(=O)OC(C)(C)C)C(=O)OC(C)(C)C)CC1=NC=CN1CC(=O)OC(C)(C)C XULCLDSGJMZTHS-YDAXCOIMSA-N 0.000 description 1
- 125000005883 dithianyl group Chemical group 0.000 description 1
- POULHZVOKOAJMA-UHFFFAOYSA-M dodecanoate Chemical compound CCCCCCCCCCCC([O-])=O POULHZVOKOAJMA-UHFFFAOYSA-M 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 229940009662 edetate Drugs 0.000 description 1
- 229960001484 edetic acid Drugs 0.000 description 1
- 150000002081 enamines Chemical class 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 125000004185 ester group Chemical group 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- 125000005678 ethenylene group Chemical group [H]C([*:1])=C([H])[*:2] 0.000 description 1
- 125000001033 ether group Chemical group 0.000 description 1
- 235000019439 ethyl acetate Nutrition 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-L fumarate(2-) Chemical compound [O-]C(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-L 0.000 description 1
- 150000002258 gallium Chemical class 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000024924 glomerular filtration Effects 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- JFCQEDHGNNZCLN-UHFFFAOYSA-L glutarate(2-) Chemical compound [O-]C(=O)CCCC([O-])=O JFCQEDHGNNZCLN-UHFFFAOYSA-L 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 150000002357 guanidines Chemical class 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000005844 heterocyclyloxy group Chemical group 0.000 description 1
- MELUCTCJOARQQG-UHFFFAOYSA-N hex-2-yne Chemical compound CCCC#CC MELUCTCJOARQQG-UHFFFAOYSA-N 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 102000046689 human FOLH1 Human genes 0.000 description 1
- XGIHQYAWBCFNPY-AZOCGYLKSA-N hydrabamine Chemical compound C([C@@H]12)CC3=CC(C(C)C)=CC=C3[C@@]2(C)CCC[C@@]1(C)CNCCNC[C@@]1(C)[C@@H]2CCC3=CC(C(C)C)=CC=C3[C@@]2(C)CCC1 XGIHQYAWBCFNPY-AZOCGYLKSA-N 0.000 description 1
- 229940042795 hydrazides for tuberculosis treatment Drugs 0.000 description 1
- 150000002429 hydrazines Chemical class 0.000 description 1
- 150000007857 hydrazones Chemical class 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-N hydrogen thiocyanate Natural products SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 150000002443 hydroxylamines Chemical class 0.000 description 1
- 125000002962 imidazol-1-yl group Chemical group [*]N1C([H])=NC([H])=C1[H] 0.000 description 1
- 125000005945 imidazopyridyl group Chemical group 0.000 description 1
- 150000002466 imines Chemical class 0.000 description 1
- 230000002055 immunohistochemical effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011503 in vivo imaging Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 125000003427 indacenyl group Chemical group 0.000 description 1
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 1
- 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 description 1
- 150000002471 indium Chemical class 0.000 description 1
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 1
- 125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000000266 injurious effect Effects 0.000 description 1
- 125000001905 inorganic group Chemical group 0.000 description 1
- 229910017053 inorganic salt Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- XMBWDFGMSWQBCA-RNFDNDRNSA-M iodine-131(1-) Chemical compound [131I-] XMBWDFGMSWQBCA-RNFDNDRNSA-M 0.000 description 1
- 230000001678 irradiating effect Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 239000012948 isocyanate Substances 0.000 description 1
- 150000002513 isocyanates Chemical class 0.000 description 1
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
- 108010076560 isospaglumic acid Proteins 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 150000002540 isothiocyanates Chemical class 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 229940001447 lactate Drugs 0.000 description 1
- JYTUSYBCFIZPBE-AMTLMPIISA-M lactobionate Chemical compound [O-]C(=O)[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O JYTUSYBCFIZPBE-AMTLMPIISA-M 0.000 description 1
- 229940099584 lactobionate Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229940070765 laurate Drugs 0.000 description 1
- 150000007517 lewis acids Chemical class 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000005228 liver tissue Anatomy 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 1
- 239000000347 magnesium hydroxide Substances 0.000 description 1
- 229910001862 magnesium hydroxide Inorganic materials 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-L malate(2-) Chemical compound [O-]C(=O)C(O)CC([O-])=O BJEPYKJPYRNKOW-UHFFFAOYSA-L 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-M mandelate Chemical compound [O-]C(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-M 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- XWBUDPXCXXQEOU-UHFFFAOYSA-N methyl 2,4-diamino-4-oxobutanoate Chemical compound COC(=O)C(N)CC(N)=O XWBUDPXCXXQEOU-UHFFFAOYSA-N 0.000 description 1
- 229940102396 methyl bromide Drugs 0.000 description 1
- LRMHVVPPGGOAJQ-UHFFFAOYSA-N methyl nitrate Chemical compound CO[N+]([O-])=O LRMHVVPPGGOAJQ-UHFFFAOYSA-N 0.000 description 1
- JZMJDSHXVKJFKW-UHFFFAOYSA-M methyl sulfate(1-) Chemical compound COS([O-])(=O)=O JZMJDSHXVKJFKW-UHFFFAOYSA-M 0.000 description 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 1
- 125000004593 naphthyridinyl group Chemical group N1=C(C=CC2=CC=CN=C12)* 0.000 description 1
- 229950006327 napsilate Drugs 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 125000006574 non-aromatic ring group Chemical group 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000009206 nuclear medicine Methods 0.000 description 1
- UMIPWJGWASORKV-UHFFFAOYSA-N oct-1-yne Chemical compound CCCCCCC#C UMIPWJGWASORKV-UHFFFAOYSA-N 0.000 description 1
- QCQALVMFTWRCFI-UHFFFAOYSA-N oct-2-yne Chemical compound CCCCCC#CC QCQALVMFTWRCFI-UHFFFAOYSA-N 0.000 description 1
- UDEISTCPVNLKRJ-UHFFFAOYSA-N oct-3-yne Chemical compound CCCCC#CCC UDEISTCPVNLKRJ-UHFFFAOYSA-N 0.000 description 1
- GZTNBKQTTZSQNS-UHFFFAOYSA-N oct-4-yne Chemical compound CCCC#CCCC GZTNBKQTTZSQNS-UHFFFAOYSA-N 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-M oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC([O-])=O ZQPPMHVWECSIRJ-KTKRTIGZSA-M 0.000 description 1
- 229940049964 oleate Drugs 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 150000002891 organic anions Chemical class 0.000 description 1
- 125000000962 organic group Chemical group 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- WCPAKWJPBJAGKN-UHFFFAOYSA-N oxadiazole Chemical group C1=CON=N1 WCPAKWJPBJAGKN-UHFFFAOYSA-N 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- IVMHDOBGNQOUHO-UHFFFAOYSA-N oxathiane Chemical group C1CCSOC1 IVMHDOBGNQOUHO-UHFFFAOYSA-N 0.000 description 1
- 150000002923 oximes Chemical class 0.000 description 1
- 239000006174 pH buffer Substances 0.000 description 1
- 229940014662 pantothenate Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 238000005192 partition Methods 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 239000000816 peptidomimetic Substances 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 125000001792 phenanthrenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3C=CC12)* 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 1
- 229940075930 picrate Drugs 0.000 description 1
- OXNIZHLAWKMVMX-UHFFFAOYSA-M picrate anion Chemical compound [O-]C1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-M 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 125000005936 piperidyl group Chemical group 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 125000003367 polycyclic group Chemical group 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229920000570 polyether Polymers 0.000 description 1
- 229920002643 polyglutamic acid Polymers 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 244000144977 poultry Species 0.000 description 1
- 235000013594 poultry meat Nutrition 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- QROGIFZRVHSFLM-UHFFFAOYSA-N prop-1-enylbenzene Chemical group CC=CC1=CC=CC=C1 QROGIFZRVHSFLM-UHFFFAOYSA-N 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- MWWATHDPGQKSAR-UHFFFAOYSA-N propyne Chemical compound CC#C MWWATHDPGQKSAR-UHFFFAOYSA-N 0.000 description 1
- 201000005825 prostate adenocarcinoma Diseases 0.000 description 1
- 208000023958 prostate neoplasm Diseases 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 235000004252 protein component Nutrition 0.000 description 1
- 125000002577 pseudohalo group Chemical group 0.000 description 1
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 1
- 125000003072 pyrazolidinyl group Chemical group 0.000 description 1
- 125000002755 pyrazolinyl group Chemical group 0.000 description 1
- 125000001725 pyrenyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 239000002510 pyrogen Substances 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 125000001422 pyrrolinyl group Chemical group 0.000 description 1
- 230000005258 radioactive decay Effects 0.000 description 1
- 238000000163 radioactive labelling Methods 0.000 description 1
- 239000000700 radioactive tracer Substances 0.000 description 1
- 238000002601 radiography Methods 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000006722 reduction reaction Methods 0.000 description 1
- 238000006268 reductive amination reaction Methods 0.000 description 1
- 208000016691 refractory malignant neoplasm Diseases 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 125000006413 ring segment Chemical group 0.000 description 1
- 235000005713 safflower oil Nutrition 0.000 description 1
- 239000003813 safflower oil Substances 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- MOODSJOROWROTO-UHFFFAOYSA-N salicylsulfuric acid Chemical compound OC(=O)C1=CC=CC=C1OS(O)(=O)=O MOODSJOROWROTO-UHFFFAOYSA-N 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- DCKVNWZUADLDEH-UHFFFAOYSA-N sec-butyl acetate Chemical compound CCC(C)OC(C)=O DCKVNWZUADLDEH-UHFFFAOYSA-N 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 238000005556 structure-activity relationship Methods 0.000 description 1
- 125000005017 substituted alkenyl group Chemical group 0.000 description 1
- 125000005415 substituted alkoxy group Chemical group 0.000 description 1
- 125000000547 substituted alkyl group Chemical group 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 150000003456 sulfonamides Chemical class 0.000 description 1
- 150000003457 sulfones Chemical class 0.000 description 1
- 229940071103 sulfosalicylate Drugs 0.000 description 1
- 150000003462 sulfoxides Chemical class 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 125000001935 tetracenyl group Chemical group C1(=CC=CC2=CC3=CC4=CC=CC=C4C=C3C=C12)* 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000005944 tetrahydroimidazopyridyl group Chemical group 0.000 description 1
- 125000005888 tetrahydroindolyl group Chemical group 0.000 description 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
- 125000003507 tetrahydrothiofenyl group Chemical group 0.000 description 1
- 125000004632 tetrahydrothiopyranyl group Chemical group S1C(CCCC1)* 0.000 description 1
- 125000001113 thiadiazolyl group Chemical group 0.000 description 1
- 125000004927 thianaphthalenyl group Chemical group S1C(C=CC2=CC=CC=C12)* 0.000 description 1
- 125000001984 thiazolidinyl group Chemical group 0.000 description 1
- 125000002769 thiazolinyl group Chemical group 0.000 description 1
- 125000002813 thiocarbonyl group Chemical group *C(*)=S 0.000 description 1
- 150000003568 thioethers Chemical class 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 150000007944 thiolates Chemical group 0.000 description 1
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 1
- 238000003325 tomography Methods 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 125000002088 tosyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])[H])S(*)(=O)=O 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 125000004306 triazinyl group Chemical group 0.000 description 1
- ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical compound [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 description 1
- ITMCEJHCFYSIIV-UHFFFAOYSA-N triflic acid Chemical group OS(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-N 0.000 description 1
- 125000003960 triphenylenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3C3=CC=CC=C3C12)* 0.000 description 1
- 229960004441 tyrosine Drugs 0.000 description 1
- 229930195735 unsaturated hydrocarbon Natural products 0.000 description 1
- 150000003672 ureas Chemical class 0.000 description 1
- 150000003673 urethanes Chemical class 0.000 description 1
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical class CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
- C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0402—Organic compounds carboxylic acid carriers, fatty acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
- A61K51/0478—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group complexes from non-cyclic ligands, e.g. EDTA, MAG3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
- A61K51/0482—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D255/00—Heterocyclic compounds containing rings having three nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D249/00 - C07D253/00
- C07D255/02—Heterocyclic compounds containing rings having three nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D249/00 - C07D253/00 not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic System
- C07F5/003—Compounds containing elements of Groups 3 or 13 of the Periodic System without C-Metal linkages
Abstract
Description
[定義]
ここで便宜上、本明細書中及び添付の請求項中で使用する特定の用語を定義する。
「ヒドロキシアルキル」という用語は、前記炭素原子数のアルキル基であって、アルキル基の水素原子のうち1個以上が−OH基で置き換えられたものを意味する。ヒドロキシアルキル基の例としては、−CH2OH、−CH2CH2OH、−CH2CH2CH2OH、−CH2CH2CH2CH2OH、−CH2CH2CH2CH2CH2OH、−CH2CH2CH2CH2CH2CH2OH及びこれらの分枝形態が挙げられるが、これらに限定されない。
[キレート剤化合物及びその合成]
本方法は、式I及び式IIの化合物並びにこれらの薬学的に許容可能な塩、エステル又は溶媒和物を対象としている。式I及び式IIの化合物はいずれも、PSMAを発現させる前立腺癌組織の放射線造影用途及び放射線療法用途に有望なリガンドである。前記化合物は、リンカー又はスペーサを用いて結合された第1末端基及び第2末端基を包含する。第1末端基は、グルタミン−ウレア−リジン(GUL)部位又はグルタミン−ウレア−グルタミン(GUG)部位(以降参照)を含むトリペプチドであり、また一方、第2末端基は放射性核種キレート剤を含む。
また一方、第2末端基は、
製剤
上述の通り、式I又は式IIで表される化合物の錯体は、急速増殖細胞、例えばPSMAを発現させる前立腺癌細胞を処置するための放射線造影剤として又は治療薬として使用するのに適した放射性核種を1種以上含有し得る。したがって、一実施形態では、金属と、式I又は式IIの化合物、これらの塩、溶媒和、立体異性体又は互変異性体と、薬学的に許容可能なキャリアと、を包含する錯体を含む医薬組成物が提供される。
化合物と金属との一般的な錯体形成手順。本明細書において例示する場合、インジウムを金属として使用する。しかし、分かるように、本明細書に記載された他の金属を用いて同様の合成手順を行うことで、式Iの化合物と錯体を形成してもよい。従って、様々な実施例ではインジウムが具体的に示されているが、Y、Gs、Lu錯体も同様に包含されると考えられる。その上、これら元素の様々な同位元素、例えば111In、90Y、68Ga、64Cu又は177Luを錯体化してもよいとも考えられる。
インジウム錯体を構成するための一般的な実験条件
式Iの化合物のインジウム錯体は、市販のInCl3を式Iの化合物と接触させることを伴う反応から好都合に単離される。手短に言えば、アセトニトリルとリン酸緩衝液の1:1の等容積混合液中の適切な式Iの化合物(10-6M〜10-4M)をInCl3と共に密封バイアル瓶に入れる。反応混合物を100℃で30〜45分間加熱させる。冷却後、反応は逆相高圧液体クロマトグラフィー(RP−HPLC)によって純度の解析を行い、また、必要があれば、RP−HPLC又はC18 Sep Pakカラムを用いて精製してもよい。精製後の所望の生成物の平均収率は約20%〜約99%の範囲である。ただし、HPLCでの精製後の放射化学的純度(RCP)は、「無担体」生成物では常に≧95%であった。初期成果では10-6M程度の低い濃度での放射標識が実証されたが、この試薬濃度での放射化学的収率度(RCY)は≦80%であった。95%を上回るRCYを得るために、反応混合物の反応温度及び試薬濃度を10-4Mまで増大させた。
代表的な式I及び式IIの化合物の合成
A.スキーム1は、GUL−HEX−EDTA−DOTA類似物及びGUG−HEX−EDTA−DOTA類似物のための一般合成経路図である。
[合成及び特性評価]
[実施例1]
(14S,18S)−1−(1−(2−(ビス(カルボキシメチル)アミノ)−2−オキソエチル)−1H−イミダゾル−2−イル)−8,16−ジオキソ−2−(4−((1−(3−(2−(4,7,10−トリス(カルボキシメチル)−1,4,7,10−テトラアザシクロドデカン−1−イル)アセトアミド)プロピル)−1H−1,2,3−トリアゾル−4−イル)メトキシ)ベンジル)−2,9,15,17−テトラアザイコサン−14,18,20−トリカルボン酸インジウム錯体(MIP−1445)
[工程2]6−(((1−(2−(ビス(2−(tert−ブトキシ)−2−オキソエチル)アミノ)−2−オキソエチル)−1H−イミダゾル−2−イル)メチル)(4−(プロパ−2−イン−1−イルオキシ)ベンジル)アミノ)ヘキサン酸
[工程3](14S,18S)−トリ−tert−ブチル−1−(1−(2−(ビス(2−(tert−ブトキシ)−2−オキソエチル)アミノ)−2−オキソエチル)−1H−イミダゾル−2−イル),−8,16−ジオキソ−2−(4−(プロパ−2−イン−1−イルオキシ)ベンジル)−2,9,15,17−テトラアザイコサン−14,18,20−トリカルボキシレート
[工程4](14S,18S)−トリ−tert−ブチル2−(4−((1−(3−アミノプロピル)−1H−1,2,3−トリアゾル−4−イル)メトキシ)ベンジル)−1−(1−(2−(ビス(2−(tert−ブトキシ)−2−オキソエチル)アミノ)−2−オキソエチル)−1H−イミダゾル−2−イル)−8,16−ジオキソ−2,9,15,17−テトラアザイコサン−14,18,20−トリカルボキシレート
[工程5]((14S,18S)−1−(1−(2−(ビス(カルボキシメチル)アミノ)−2−オキソエチル)−1H−イミダゾル−2−イル)−8,16−ジオキソ−2−(4−((1−(3−(2−(4,7,10−トリス(カルボキシメチル)−1,4,7,10−テトラアザシクロドデカン−1−イル)アセトアミド)プロピル)−1H−1,2,3−トリアゾル−4−イル)メトキシ)ベンジル)−2,9,15,17−テトラアザイコサン−14,18,20−トリカルボン酸(MIP−1459)
[工程6]((14S,18S)−トリ−tert−ブチル−1−(1−(2−(ビス(2−(tert−ブトキシ)−2−オキソエチル)−アミノ)−2−オキソエチル)−1H−イミダゾル−2−イル)−8,16−ジオキソ−2−(4−((1−(3−(2−(4,7,10−トリス(2−(tert−ブトキシ)−2−オキソエチル)−1,4,7,10−テトラアザシクロドデカン−1−イル)アセトアミド)プロピル)−1H−1,2,3−トリアゾル−4−イル)メトキシ)ベンジル)−2,9,15,17−テトラアザイコサン−14,18,20−トリカルボキシレート(MIP−1459−ブチル−エステルt)の合成
[工程7](14S,18S)−1−(1−(2−(ビス(カルボキシメチル)アミノ)−2−オキソエチル)−1H−イミダゾル−2−イル)−8,16−ジオキソ−2−(4−((1−(3−(2−(4,7,10−トリス(カルボキシメチル)−1,4,7,10−テトラアザシクロドデカン−1−イル)アセトアミド)プロピル)−1H−1,2,3−トリアゾル−4−イル)メトキシ)ベンジル)−2,9,15,17−テトラアザイコサン−14,18,20−トリカルボン酸インジウム錯体(MIP−1445)
((14S,18S)−トリ−tert−ブチル1−(1−(2−(ビス(2−(tert−ブトキシ)−2−オキソエチル)アミノ)−2−オキソエチル)−1H−イミダゾル−2−イル)−8,16−ジオキソ−2−(4−((1−(3−(2−(4,7,10−トリス(2−(tert−ブトキシ)−2−オキソエチル)−1,4,7,10−テトラアザシクロドデカン−1−イル)アセトアミド)プロピル)−1H−1,2,3−トリアゾル−4−イル)メトキシ)ベンジル)−2,9,15,17−テトラアザイコサン−14,18,20−トリカルボキシレート(21mg,0.012ミリモル)のTFA(2.0mL)及びDCM(2.0mL)溶液を室温において一晩撹拌した。溶媒を窒素流の下で蒸発させて未精製の((14S,18S)−1−(1−(2−(ビス(カルボキシメチル)アミノ)−2−オキソエチル)−1H−イミダゾル−2−イル)−8,16−ジオキソ−2−(4−((1−(3−(2−(4,7,10−トリス(カルボキシメチル)−1,4,7,10−テトラアザシクロドデカン−1−イル)アセトアミド)プロピル)−1H−1,2,3−トリアゾル−4−イル)メトキシ)ベンジル)−2,9,15,17−テトラアザイコサン−14,18,20−トリカルボン酸(MIP−1459)を得て、それをInCl3(10mg)を含む酢酸アンモニウム(0.30mL、0.50N)の水(0.50mL)溶液に溶解させた。反応混合物を95℃において1時間加熱し、HPLCによって精製することで生成物(MIP−1445(1mg))が得られた。MS(ESI),714.9(M/2+H)+。
[実施例2]
(14S,18S)−1−(1−(カルボキシメチル)−1H−イミダゾル−2−イル)−8,16−ジオキソ−2−(4−((1−(3−(2−(4,7,10−トリス(カルボキシメチル)−1,4,7,10−テトラアザシクロドデカン−1−イル)アセトアミド)プロピル)−1H−1,2,3−トリアゾル−4−イル)メトキシ)ベンジル)−2,9,15,17−テトラアザイコサン−14,18,20−トリカルボン酸インジウム錯体(MIP−1470)
[工程2](14S,18S)−トリ−tert−ブチル1−(1−(2−(tert−ブトキシ)−2−オキソエチル)−1H−イミダゾル−2−イル),−8,16−ジオキソ−2−(4−(プロパ−2−イン−1−イルオキシ)ベンジル)−2,9,15,17−テトラアザイコサン−14,18,20−トリカルボキシレート
[工程3](14S,18S)−トリ−tert−ブチル2−(4−((1−(3−アミノプロピル)−1H−1,2,3−トリアゾル−4−イル)メトキシ)ベンジル)−1−(1−(2−(tert−ブトキシ)−2−オキソエチル)−1H−イミダゾル−2−イル)−8,16−ジオキソ−2,9,15,17−テトラアザイコサン−14,18,20−トリカルボキシレート
[工程4](14S,18S)−1−(1−(カルボキシメチル)−1H−イミダゾル−2−イル)−8,16−ジオキソ−2−(4−((1−(3−(2−(4,7,10−トリス(カルボキシメチル)−1,4,7,10−テトラアザシクロドデカン−1−イル)アセトアミド)プロピル)−1H−1,2,3−トリアゾル−4−イル)メトキシ)ベンジル)−2,9,15,17−テトラアザイコサン−14,18,20−トリカルボン酸(MIP−1469)
[工程5](14S,18S)−1−(1−(カルボキシメチル)−1H−イミダゾル−2−イル)−8,16−ジオキソ−2−(4−((1−(3−(2−(4,7,10−トリス(カルボキシメチル)−1,4,7,10−テトラアザシクロドデカン−1−イル)アセトアミド)プロピル)−1H−1,2,3−トリアゾル−4−イル)メトキシ)ベンジル)−2,9,15,17−テトラアザイコサン−14,18,20−トリカルボン酸インジウム錯体(MIP−1470)
(14S,18S)−1−(1−(カルボキシメチル)−1H−イミダゾル−2−イル)−8,16−ジオキソ−2−(4−((1−(3−(2−(4,7,10−トリス(カルボキシメチル)−1,4,7,10−テトラアザシクロドデカン−1−イル)アセトアミド)プロピル)−1H−1,2,3−トリアゾル−4−イル)メトキシ)ベンジル)−2,9,15,17−テトラアザイコサン−14,18,20−トリカルボン酸(14.3mg、0.0119)と、酢酸アンモニウム(1.0mL,0.50N)との水(2.0mL)溶液にInCl3(9mg)を加えた。反応混合物を100℃において45分間加熱し、HPLCによって精製することでMIP−1470(2.9mg)が得られた。MS(ESI),657.2(M/2+H)+。
[実施例3]
(8S,15S,19S)−8−アミノ−2,9,17−トリオキソ−1−(4,7,10−トリス(カルボキシメチル)−1,4,7,10−テトラアザシクロドデカン−1−イル)−3,10,16,18−テトラアザヘニコサン−15,19,21−トリカルボン酸インジウム錯体(MIP−1458)
[工程2](8S,15S,19S)−8−アミノ−2,9,17−トリオキソ−1−(4,7,10−トリス(カルボキシメチル)−1,4,7,10−テトラアザシクロドデカン−1−イル)−3,10,16,18−テトラアザヘニコサン−15,19,21−トリカルボン酸(MIP−1457)
[工程3](8S,15S,19S)−8−アミノ−2,9,17−トリオキソ−1−(4,7,10−トリス(カルボキシメチル)−1,4,7,10−テトラアザシクロドデカン−1−イル)−3,10,16,18−テトラアザヘニコサン−15,19,21−トリカルボン酸インジウム錯体(MIP−1458)
(8S,15S,19S)−8−アミノ−2,9,17−トリオキソ−1−(4,7,10−トリス(カルボキシメチル)−1,4,7,10−テトラアザシクロドデカン−1−イル)−3,10,16,18−テトラアザヘニコサン−15,19,21−トリカルボン酸(18mg)と、酢酸アンモニウム(0.50mL、0.50N)との水(2.0mL)溶液にInCl3(9mg)を加えた。反応混合物を100℃において45分間加熱し、HPLCによって精製することで表題の生成物(MIP−1458(4.0mg))が得られた。MS(ESI),946.4(M+H)+。
[実施例4]
(16S,20S)−10,18−ジオキソ−1−((4−((1,4,7,10−テトラキス(カルボキシメチル)−1,4,7,10−テトラアザシクロドデカン−2−イル)メチル)フェニル)アミノ)−1−チオキソ−2,11,17,19−テトラアザドコサン−16,20,22−トリカルボン酸(MIP−1512)の合成
[実施例5]
(16S,20S)−10,18−ジオキソ−1−((4−((1,4,7,10−テトラキス(カルボキシメチル)−1,4,7,10−テトラアザシクロドデカン−2−イル)メチル)フェニル)アミノ)−1−チオキソ−2,11,17,19−テトラアザドコサン−16,20,22−トリカルボキシレートLu錯体(Lu−MIP−1512)の合成
[実施例6]
(10S,17S,21S)−10−(2−カルボキシエチル)−8,11,19−トリオキソ−1−((4−((1,4,7,10−テトラキス(カルボキシメチル)−1,4,7,10−テトラアザシクロドデカン−2−イル)メチル)フェニル)アミノ)−1−チオキソ−2,9,12,18,20−ペンタアザトリコサン−17,21,23−トリカルボン酸(MIP−1523)の合成は、前記スキーム5に示した通りに行った。
[実施例7]
(10S,17S,21S)−10−(2−カルボキシエチル)−8,11,19−トリオキソ−1−((4−((1,4,7,10−テトラキス(カルボキシメチル)−1,4,7,10−テトラアザシクロドデカン−2−イル)メチル)フェニル)アミノ)−1−チオキソ−2,9,12,18,20−ペンタアザトリコサン−17,21,23−トリカルボキシレートLu錯体(Lu−MIP−1523)の合成は、前記スキーム5に示した通りに行った。
[実施例8]
(10S,17S,21S)−10−ベンジル−8,11,19−トリオキソ−1−((4−((1,4,7,10−テトラキス(カルボキシメチル)−1,4,7,10−テトラアザシクロドデカン−2−イル)メチル)フェニル)アミノ)−1−チオキソ−2,9,12,18,20−ペンタアザトリコサン−17,21,23−トリカルボン酸(MIP−1530)の合成
[実施例9]
(10S,17S,21S)−10−ベンジル−8,11,19−トリオキソ−1−((4−((1,4,7,10−テトラキス(カルボキシメチル)−1,4,7,10−テトラアザシクロドデカン−2−イル)メチル)フェニル)アミノ)−1−チオキソ−2,9,12,18,20−ペンタアザトリコサン−17,21,23−トリカルボキシレートLu錯体(Lu−MIP−1530)の合成
[実施例10]
(3S,7S,14S,17S)−14−ベンジル−5,13,16−トリオキソ−17−(6−(3−(4−(((S)−1,4,7,10−テトラキス(カルボキシメチル)−1,4,7,10−テトラアザシクロドデカン−2−イル)メチル)フェニル)チオウレイド)ヘキサンアミド)−4,6,12,15−テトラアザノナデカン−1,3,7,19−テトラカルボン酸(MIP−1531)の合成
[実施例11]
(3S,7S,14S,17S)−14−ベンジル−5,13,16−トリオキソ−17−(6−(3−(4−(((S)−1,4,7,10−テトラキス(カルボキシメチル)−1,4,7,10−テトラアザシクロドデカン−2−イル)メチル)フェニル)チオウレイド)ヘキサンアミド)−4,6,12,15−テトラアザノナデカン−1,3,7,19−テトラカルボキシレートLu錯体(Lu−MIP−1531)の合成
[実施例12]
(10S,17S,21S)−10−(4−フルオロベンジル)−8,11,19−トリオキソ−1−((4−((1,4,7,10−テトラキス(カルボキシメチル)−1,4,7,10−テトラアザシクロドデカン−2−イル)メチル)フェニル)アミノ)−1−チオキソ−2,9,12,18,20−ペンタアザトリコサン−17,21,23−トリカルボン酸(MIP−1546)の合成は、前記スキーム6に示した通りに行った。
[実施例13]
(10S,17S,21S)−10−(4−フルオロベンジル)−8,11,19−トリオキソ−1−((4−((1,4,7,10−テトラキス(カルボキシメチル)−1,4,7,10−テトラアザシクロドデカン−2−イル)メチル)フェニル)アミノ)−1−チオキソ−2,9,12,18,20−ペンタアザトリコサン−17,21,23−トリカルボキシレートLu錯体(Lu−MIP−1546)の合成は、前記スキーム6に示した通りに行った。
[実施例14]
(10S,17S,21S)−10−(ナフタレン−2−イルメチル)−8,11,19−トリオキソ−1−((4−((1,4,7,10−テトラキス(カルボキシメチル)−1,4,7,10−テトラアザシクロドデカン−2−イル)メチル)フェニル)アミノ)−1−チオキソ−2,9,12,18,20−ペンタアザトリコサン−17,21,23−トリカルボン酸(MIP−1545)の合成
[実施例15]
(10S,17S,21S)−10−(ナフタレン−2−イルメチル)−8,11,19−トリオキソ−1−((4−((1,4,7,10−テトラキス(カルボキシメチル)−1,4,7,10−テトラアザシクロドデカン−2−イル)メチル)フェニル)アミノ)−1−チオキソ−2,9,12,18,20−ペンタアザトリコサン−17,21,23−トリカルボキシレートLu錯体(Lu−MIP−1545)の合成
[実施例16]
(10S,13S.20S,24S)−13−(2−カルボキシエチル)−10−(4−フルオロベンジル)−8,11,14,22−テトラオキソ−1−((4−((1,4,7,10−テトラキス(カルボキシメチル)−1,4,7,10−テトラアザシクロドデカン−2−イル)メチル)フェニル)アミノ)−1−チオキソ−2,9,12,15,21,23−ヘキサアザヘキサコサン−20,24,26−トリカルボン酸(MIP−1550)の合成は、前記スキーム7に示した通りに行った。
[実施例17]
(10S,13S.20S,24S)−13−(2−カルボキシエチル)−10−(4−フルオロベンジル)−8,11,14,22−テトラオキソ−1−((4−((1,4,7,10−テトラキス(カルボキシメチル)−1,4,7,10−テトラアザシクロドデカン−2−イル)メチル)フェニル)アミノ)−1−チオキソ−2,9,12,15,21,23−ヘキサアザヘキサコサン−20,24,26−トリカルボキシレートLu錯体(Lu−MIP−1550)の合成は、前記スキーム7に示した通りに行った。
[実施例18]
(11S,16S,20S)−11−(2−カルボキシエチル)−10,13,18−トリオキソ−1−((4−((1,4,7,10−テトラキス(カルボキシメチル)−1,4,7,10−テトラアザシクロドデカン−2−イル)メチル)フェニル)アミノ)−1−チオキソ−2,9,12,17,19−ペンタアザドコサン−16,20,22−トリカルボン酸(MIP−1519)の合成
[実施例19]
(11S,16S,20S)−11−(2−カルボキシエチル)−10,13,18−トリオキソ−1−((4−((1,4,7,10−テトラキス(カルボキシメチル)−1,4,7,10−テトラアザシクロドデカン−2−イル)メチル)フェニル)アミノ)−1−チオキソ−2,9,12,17,19−ペンタアザドコサン−16,20,22−トリカルボキシレートLu錯体(Lu−MIP−1519)の合成
[実施例20]
(13S,17S)−10,15−ジオキソ−1−((4−((1,4,7,10−テトラキス(カルボキシメチル)−1,4,7,10−テトラアザシクロドデカン−2−イル)メチル)フェニル)アミノ)−1−チオキソ−2,9,14,16−テトラアザノナデカン−13,17,19−トリカルボン酸(MIP−1526)の合成
[実施例21]
(13S,17S)−10,15−ジオキソ−1−((4−((1,4,7,10−テトラキス(カルボキシメチル)−1,4,7,10−テトラアザシクロドデカン−2−イル)メチル)フェニル)アミノ)−1−チオキソ−2,9,14,16−テトラアザノナデカン−13,17,19−トリカルボキシレートLu錯体(Lu−MIP−1526)の合成
[実施例22]
(11S,16S,20S)−11−ベンジル−10,13,18−トリオキソ−1−((4−((1,4,7,10−テトラキス(カルボキシメチル)−1,4,7,10−テトラアザシクロドデカン−2−イル)メチル)フェニル)アミノ)−1−チオキソ−2,9,12,17,19−ペンタアザドコサン−16,20,22−トリカルボン酸(MIP−1548)の合成
[実施例23]
(11S,16S,20S)−11−ベンジル−10,13,18−トリオキソ−1−((4−((1,4,7,10−テトラキス(カルボキシメチル)−1,4,7,10−テトラアザシクロドデカン−2−イル)メチル)フェニル)アミノ)−1−チオキソ−2,9,12,17,19−ペンタアザドコサン−16,20,22−トリカルボキシレートLu錯体(Lu−MIP−1548)の合成
前記合成プロトコルを用いて、キレート剤が次のものから選択される部位である式I及び式IIの化合物を合成することができる。
特定の実施形態について例示しかつ説明してきたが、当該技術分野における通常の知識によれば、以下の請求項で定義するような広義の態様の技術から逸脱することなく変更及び修正が可能であると解されるべきである。
Claims (40)
- 式IIで表される化合物であって、
Wは、H、=O、−(CHR1)m−(CH2)p−、又は−(CH2)p−Uであり、
Lは、−C(O)−(C1−C10)アルキレン、−[C(O)−(CH(Z)d)−NH]jNR2R3、−C(O)−(CHR1)−(CH2)p−U−、−(C5−C14)アリール−(C1−C10)アルキレン、R7−ベンジル、−(C5−C14)ヘテロアリール−(C1−C10)アルキレン、−C(O)−[(CH2)p−V]n−(CH2)q−C(O)−U、[C(O)−CH(Z)d−NH]t−C(O)−(CHR1)m−(CH2)p−[U]r、−C(S)−NH−ベンジレン、−C(O)−NH−ベンジレン、−[C(O)−(CH(Z)d)−NH]s−ベンジレン−、又は−(C1−C10)アルキレン−NR4R5であり、
Tは、H、−(C1−C10)アルキレン、RC(O)−(C1−C10)アルキレン、NR2R3−(C1−C10)アルキレン、−(C5−C14)ヘテロアリール−(C1−C10)アルキレン、−(C5−C14)アリール−(C1−C10)アルキレン及びR6−(C5−C14)ヘテロアリーレン−(C1−C10)アルキレンからなる群から選択され、
Uは、−OR、−COR、−(C5−C14)アリーレン及びNR4R5からなる群から選択され、
Vは、−NH−、−NR2−及び−NR2R3からなる群から選択され、
Zは、−(CH2)p−COOH、−(CH2)p−(C5−C14)アリール、又は−(CH2)p−NR2R3であり、
R、Ra及びRbはそれぞれ独立して、−H、OH、−(C1−C10)アルキル、−O(C1−C10)アルキル、−NHR2又は−NR2R3であり、
R1及びR”’はそれぞれ独立して、−H、−NH2、又は−(CH2)p−Uであり、
R2、R3、R4 及びR6はそれぞれ独立して、H、結合、(C1−C10)アルキレン、F、Cl、Br、I、C(O)、C(S)、−C(S)−NH−ベンジル−、−C(O)−NH−ベンジル−、−C(O)−(C1−C10)アルキレン、−(CH2)v−NR4、−(CH2)p−NH−C(O)−(CH2)p−、−(CH2−CH2)t−NH−C(O)−(CH2)p−、−(CH2)p−COR、−(CH2)p−C(O)NH−C[(CH2)p−COR]3、−C[(CH2)p−COR]3、又は−(CH2)p−(C5−C14)ヘテロアリールであり、
R7は、−O(CH2)p−(C5−C14)ヘテロアリール−(CH2)p−Uであり、
Dは、
d、j、k、m、n、p、q、r、s、t及びvは、それぞれ独立して、0、1、2、3、4、5、6、7、8、9又は10であり、
任意のアリール、アリールアルキレン、ベンジル、ヘテロアリール、又はシクロアルキルは、−(C1−C10)アルキル、ハロゲン、−(C1−C10)ハロアルキル、−(C1−C10)アミノアルキル、−(C1−C10)ヒドロキシアルキル、−(CH2)p-C(O)−U及び−(C3−C8)シクロアルキルからなる群から選択される1個、2個又は3個の置換基で選択的に置換され、
ただし、Wが−(CH2)5−又は−CH(NH2)−(CH2)4−の場合、LはC(O)CH2−ではないことを前提とする、化合物。 - 放射性核種と、請求項1に記載の化合物と、を含む金属錯体。
- 前記放射性核種が、111In、90Y、68Ga、64Cu、153Gd、155Gd、157Gd、Fe又は177Luである、請求項3に記載の金属錯体。
- 式Iで表される化合物であって、
Wは、H又は−(CH2)p−Uであり、
Lは、−C(O)−(C1−C10)アルキレン、−[C(O)−(CH(Z)d)−NH]jNR2R3、−C(O)−(CHR1)−(CH2)p−U−、−(C5−C14)アリール−(C1−C10)アルキレン、R6O−ベンジレン、−(C5−C14)ヘテロアリール−(C1−C10)アルキレン、−C(O)−[(CH2)p−V]n−(CH2)q−C(O)−U又は[C(O)−CH(Z)d−NH]t−C(O)−(CHR1)m−(CH2)p−Uであり、
Tは、H、−(C1−C10)アルキレン、RC(O)−(C1−C10)アルキレン、NR2R3−(C1−C10)アルキレン、−(C5−C14)ヘテロアリール、−(C1−C10)アルキレン又は−(C5−C14)アリール−(C1−C10)アルキレンからなる群から選択され、
Uは、−OR、−COR及び−NR4R5からなる群から選択され、
Vは、−NH−、−NR2−及び−NR2R3からなる群から選択され、
Zは、−(CH2)p−COOH又は−(CH2)p−NR2R3であり、
R、Ra及びRbはそれぞれ独立して、−H、OH、−(C1−C10)アルキル、−O(C1−C10)アルキル又は−NHR2であり、
R1及びR”’はそれぞれ独立して、−H又は−NH2であり、
R2、R3、R4 及びR5はそれぞれ独立して、H、結合、(C1−C10)アルキレン、F、Cl、Br、I、C(O)、C(S)、−C(S)−NH−ベンジル−、−C(O)−NH−ベンジル−、−C(O)−(C1−C10)アルキレン、−(CH2)p−NH−C(O)−(CH2)p−、−(CH2−CH2)t−NH−C(O)−(CH2)p−、−(CH2)p−COR、−(CH2)p−C(O)NH−C[(CH2)p−COR]3、−C[(CH2)p−COR]3、又は−(CH2)p−(C5−C14)ヘテロアリールであり、
R6は、−O(CH2)p−(C5−C14)ヘテロアリール−(CH2)p−Uであり、
Dは、
d、j、k、m、n、p及びtは、それぞれ独立して、0、1、2、3、4、5又は6であり、
任意のアリール、ヘテロアリール又はシクロアルキルは、−(C1−C10)アルキル、(C1−C10)ハロアルキル、−(C1−C10)アミノアルキル、−(C1−C10)ヒドロキシアルキル、−(CH2)p-C(O)−U及び−(C3−C8)シクロアルキルからなる群から選択される1個、2個又は3個の置換基で選択的に置換され、
ただし、Wが−(CH2)5−又は−CH(NH2)−(CH2)4−の場合、LはC(O)CH2−ではないことを前提とする、化合物。 - Xが(CHR1)mであり、YがC(O)であり、Wが水素であり、そしてkが5である、請求項6に記載の化合物。
- Lが−C(O)CH2−であり、そしてTが水素である、請求項6に記載の化合物。
- R1が水素であり、そしてmが2である、請求項6に記載の化合物。
- Lが−C(O)−[(CH2)p−V]n−(CH2)q−C(O)−U又は−C(O)−(C1−C10)アルキレンである、請求項6に記載の化合物。
- Lが−C(O)メチレンである、請求項10に記載の化合物。
- Lが−C(O)−[(CH2)p−V]n−(CH2)q−C(O)−Uであり、そしてTが水素である、請求項10に記載の化合物。
- VがNR2であり、nが2であり、そしてqが1である、請求項12に記載の化合物。
- UがNR2R3である、請求項12に記載の化合物。
- R2が水素であり、そしてR3が−(CH2)2−NH−C(O)−(CH2)−である、請求項14に記載の化合物。
- LがOR6−ベンジレンであり、そしてTが−(C5−C14)ヘテロアリール−(C1−C10)アルキレンである、請求項6に記載の化合物。
- ヘテロアリールがイミダゾールであって、−(C1−C10)アルキレン−C(O)−Uで更に置換されている、請求項16に記載の化合物。
- Wが−(CH2)−COOHであり、kが1であり、Lが−[C(O)−(CH(Z)d)−NH]j−NR2R3であり、そしてTが水素である、請求項9に記載の化合物。
- R2が水素であり、R3がC(O)CH2−であり、そしてjが4である、請求項21に記載の化合物。
- W及びTが水素であり、kが5であり、そしてLが[C(O)−CH(Z)d−NH]t−C(O)−(CHR1)m−(CH2)p−Uである、請求項9に記載の化合物。
- Zが−(CH2)4−NR2R3であり、そしてUが−NR4R5である、請求項23に記載の化合物。
- m及びtが1であり、pが4であり、そしてR1が−NH2である、請求項23に記載の化合物。
- R4が水素であり、そしてR5がC(O)メチレンである、請求項24に記載の化合物。
- R2及びR3がそれぞれ独立して−(CH2)p−(C5−C14)ヘテロアリールである、請求項24に記載の化合物。
- pが1であり、そしてヘテロアリールがイミダゾールであって、−(C1−C10)アルキレン−C(O)−Uで更に置換されている、請求項23に記載の化合物。
- 放射性核種と、請求項6に記載の化合物と、を含む、金属錯体。
- 前記放射性核種が、111In、90Y、68Ga、64Cu、153Gd、155Gd、157Gd、Fe又は177Luからなる群から選択される、請求項30に記載の金属錯体。
- 請求項6に記載の化合物若しくは請求項28に記載の金属錯体又はそれらの薬学的に許容可能な塩、溶媒和物若しくはエステルと、薬学的に許容可能なキャリアと、を含む、医薬組成物。
- 請求項30に記載の金属錯体又はその薬学的に許容可能な塩若しくは溶媒和物の有効な量を患者に投与する工程と、患者の1つ以上の領域のX線画像を記録する工程と、を含む、患者の1つ以上の領域のX線画像を得る方法。
- 前立腺特異的膜抗原(PSMA)を発現させる1個以上の組織のX線画像を得る方法であって、前記方法が、
(a)PSMAを発現させる前記の1個以上の組織を、放射性核種と請求項6の化合物又はその薬学的に許容可能な塩若しくは溶媒和物とを含む金属錯体に接触させる工程と、
(b)前記の1個以上の組織のX線画像を記録する工程と、を含む方法。 - 前記の1個以上の組織が、前立腺組織、脾臓組織及び腎組織から選択される、請求項35に記載の方法。
- 患者の1つ以上の領域のX線画像を得る方法であって、前記方法が、
PSMAに対する親和性を有し、かつGUL又はGUG部位を含む第1末端基と、放射性核種と錯体を形成する
前記患者の1つ以上の領域のX線画像を記録する工程と、
を含み、前記リンカーが、式−CO2Jでそれぞれ表される少なくとも2個のカルボキシル部位を含み、前記式において、Jはそれぞれ同一又は異なっていてよく、しかもそれぞれ独立して、H、低級アルキル及び薬学的に許容可能な有機塩又は無機塩から選択される、方法。 - 前記リンカーは少なくとも3個のカルボキシル部位を含む、請求項37に記載の方法。
- 前記リンカーは少なくとも4個のカルボキシル部位を含む、請求項37に記載の方法。
- 前記リンカーは少なくとも5個のカルボキシル部位を含む、請求項37に記載の方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161515674P | 2011-08-05 | 2011-08-05 | |
US61/515,674 | 2011-08-05 | ||
PCT/US2012/049644 WO2013022797A1 (en) | 2011-08-05 | 2012-08-03 | Radiolabeled prostate specific membrane antigen inhibitors |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2014524419A true JP2014524419A (ja) | 2014-09-22 |
JP5843338B2 JP5843338B2 (ja) | 2016-01-13 |
Family
ID=47627059
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2014524142A Active JP5843338B2 (ja) | 2011-08-05 | 2012-08-03 | 放射標識された前立腺特異的膜抗原阻害剤 |
Country Status (10)
Country | Link |
---|---|
US (2) | US8926944B2 (ja) |
EP (2) | EP2739316B1 (ja) |
JP (1) | JP5843338B2 (ja) |
AU (1) | AU2012294639B2 (ja) |
CA (1) | CA2844151C (ja) |
ES (1) | ES2732060T3 (ja) |
HU (1) | HUE045028T2 (ja) |
PL (1) | PL2739316T3 (ja) |
TR (1) | TR201910084T4 (ja) |
WO (1) | WO2013022797A1 (ja) |
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2018529765A (ja) * | 2015-09-21 | 2018-10-11 | ペドロ アナスタシオ セラノ−オヘダ | 癌を治療するためのグルタミン−高z元素化合物 |
JP2018537452A (ja) * | 2015-11-09 | 2018-12-20 | セルビオン カンパニー リミテッドCellbion Co,. Ltd | ペプチドチオ尿素誘導体、これを含有する放射線同位体標識化合物、およびこれを活性成分として含有する前立腺癌を処置または診断するための医薬組成物 |
JP2019519467A (ja) * | 2016-03-22 | 2019-07-11 | ザ・ジョンズ・ホプキンス・ユニバーシティ | 前立腺がんの内部放射線療法のための前立腺特異的膜抗原を標的とした高親和性薬剤 |
JP2019527740A (ja) * | 2016-06-22 | 2019-10-03 | デクステック メディカル エービー | リジン−尿素−グルタメートファーマコフォアを含む修飾デキストラン複合体 |
JP2019535754A (ja) * | 2016-11-23 | 2019-12-12 | キャンサー ターゲテッド テクノロジー エルエルシー | アルブミン結合psma阻害剤 |
JP2020516611A (ja) * | 2017-04-05 | 2020-06-11 | コーネル ユニバーシティー | 画像化および抗腫瘍治療において有用な調整可能な薬物動態を有する三官能性構築物 |
JP2020522506A (ja) * | 2017-05-30 | 2020-07-30 | ザ・ジョンズ・ホプキンス・ユニバーシティ | 前立腺がんの内部放射線療法のための前立腺特異的膜抗原をターゲットとした高親和性薬剤 |
JP2020524175A (ja) * | 2017-06-19 | 2020-08-13 | フューチャーケム カンパニー リミテッドFuturechem Co.,Ltd. | 前立腺がんの診断のための18f標識化合物およびその使用 |
JP2021506784A (ja) * | 2017-12-13 | 2021-02-22 | サイエンコンス アクスイェ セルスカプ | 鉛またはトリウム放射性核種に連結されたpsma標的化化合物を含む錯体 |
JP2021513542A (ja) * | 2018-02-06 | 2021-05-27 | ザ・ジョンズ・ホプキンス・ユニバーシティ | がん放射線治療法のための、psmaをターゲットとした放射性ハロゲン化した尿素‐ポリアミノカルボン酸塩 |
JP2021519822A (ja) * | 2018-03-30 | 2021-08-12 | フューチャーケム カンパニー リミテッドFuturechem Co.,Ltd. | 前立腺がんを診断および処置するためのpsma標的放射性医薬品 |
Families Citing this family (52)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008058192A2 (en) | 2006-11-08 | 2008-05-15 | Molecular Insight Pharmaceuticals, Inc. | Heterodimers of glutamic acid |
ES2918452T3 (es) | 2007-02-19 | 2022-07-15 | Marine Polymer Tech Inc | Composiciones hemostáticas y regímenes terapéuticos |
EP3388086B1 (en) | 2007-08-17 | 2020-10-07 | Purdue Research Foundation | Psma binding ligand-linker conjugates and methods for using |
WO2010065899A2 (en) * | 2008-12-05 | 2010-06-10 | Molecular Insight Pharmaceuticals, Inc. | Technetium-and rhenium-bis(heteroaryl)complexes and methods of use thereof |
US9951324B2 (en) | 2010-02-25 | 2018-04-24 | Purdue Research Foundation | PSMA binding ligand-linker conjugates and methods for using |
US10011632B2 (en) * | 2011-08-22 | 2018-07-03 | Siemens Medical Solutions Usa, Inc. | PSMA imaging agents |
AU2013207486A1 (en) | 2012-01-06 | 2014-08-21 | Molecular Insight Pharmaceuticals | Metal complexes of poly(carboxyl)amine-containing ligands having an affinity for carbonic anhydrase IX |
WO2014078484A1 (en) | 2012-11-15 | 2014-05-22 | Endocyte, Inc. | Conjugates for treating diseases caused by psma expressing cells |
JP6468602B2 (ja) | 2013-01-14 | 2019-02-13 | モレキュラ インサイト ファーマシューティカルズ インコーポレイテッド | トリアジン系放射性医薬品及び放射線造影剤 |
US10232058B2 (en) | 2013-10-14 | 2019-03-19 | The Johns Hopkins University | Prostate-specific membrane antigen-targeted photosensitizers for photodynamic therapy |
EP2862857A1 (en) | 2013-10-18 | 2015-04-22 | Deutsches Krebsforschungszentrum | Labeled inhibitors of prostate specific membrane antigen (PSMA), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer |
MY194484A (en) * | 2013-10-18 | 2022-11-30 | Deutsches Krebsforsch | Labeled Inhibitors of Prostate Specific Membrane Antigen (PSMA), Their use as Imaging Agents and Pharmaceutical Agents for the Treatment of Prostate Cancer |
EP3777898A3 (en) * | 2013-11-14 | 2021-04-21 | Endocyte, Inc. | Compounds for positron emission tomography |
EP3077407A4 (en) * | 2013-12-03 | 2017-07-19 | Millennium Pharmaceuticals, Inc. | Compounds and compositions for imaging gcc-expressing cells |
CN111285918A (zh) * | 2014-05-06 | 2020-06-16 | 约翰霍普金斯大学 | 用于psma靶向的成像和放射疗法的金属/放射性金属标记的psma抑制物 |
WO2016040179A1 (en) * | 2014-09-08 | 2016-03-17 | Molecular Insight Pharmaceuticals, Inc. | Organ protection in psma-targeted radionuclide therapy of prostate cancer |
EP3209336B1 (en) | 2014-10-20 | 2019-12-11 | Deutsches Krebsforschungszentrum | 18f-tagged inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer |
EP3011976A1 (en) | 2014-10-20 | 2016-04-27 | Deutsches Krebsforschungszentrum | 18F-tagged inhibitors of prostate specific membrane antigen (PSMA), their use as imaging agents |
WO2016065142A2 (en) | 2014-10-22 | 2016-04-28 | The Johns Hopkins University | New scaffolds and multifunctional intermediates for imaging psma and cancer therapy |
US10188759B2 (en) | 2015-01-07 | 2019-01-29 | Endocyte, Inc. | Conjugates for imaging |
EP3101012A1 (en) | 2015-06-04 | 2016-12-07 | Bayer Pharma Aktiengesellschaft | New gadolinium chelate compounds for use in magnetic resonance imaging |
US10869940B2 (en) | 2015-06-12 | 2020-12-22 | The Board Of Trustees Of The Leland Stanford Junior University | Targeted photoacoustic compounds, formulations, and uses thereof |
CU24524B1 (es) | 2015-09-30 | 2021-06-08 | Deutsches Krebsforsch | Inhibidores marcados con 18f mejorados del antígeno de membrana específica de próstata (psma) como agentes de formación de imágenes para cáncer de próstata |
US10688200B2 (en) * | 2015-12-31 | 2020-06-23 | Five Eleven Pharma Inc. | Urea-based prostate specific membrane antigen (PSMA) inhibitors for imaging and therapy |
EP3544964B1 (en) | 2016-11-28 | 2020-06-17 | Bayer Pharma Aktiengesellschaft | High relaxivity gadolinium chelate compounds for use in magnetic resonance imaging |
WO2018108287A1 (en) * | 2016-12-15 | 2018-06-21 | The European Atomic Energy Community (Euratom), Represented By The European Commission | Treatment of pmsa expressing cancers |
EP3618867A4 (en) | 2017-05-02 | 2021-01-20 | Cornell University | METHODS AND REAGENTS FOR AGAINST TUMOR WITH HIGHER EFFICIENCY AND LOWER TOXICITY |
WO2018233798A1 (en) | 2017-06-20 | 2018-12-27 | ITM Isotopen Technologien München AG | NOVEL PSMA BINDING AGENTS AND USE THEREOF |
CA3060143A1 (en) | 2017-05-24 | 2018-11-29 | Itm Isotopen Technologien Munchen Ag | Novel psma-binding agents and uses thereof |
WO2018236115A1 (ko) * | 2017-06-19 | 2018-12-27 | (주)퓨쳐켐 | 전립선암 진단을 위한 18f-표지된 화합물 및 그의 용도 |
EP3590911A1 (en) * | 2018-07-01 | 2020-01-08 | Studiengesellschaft Kohle MbH | Reagent and process for the site-specific deoxyfluorination of peptides |
CN112770785A (zh) | 2018-09-28 | 2021-05-07 | 海德堡大学 | 前列腺特异性膜抗原(psma)的标记抑制剂,其作为显像剂和药剂用于治疗表达psma的癌症的用途 |
AU2019382881A1 (en) | 2018-11-23 | 2021-05-20 | Bayer Aktiengesellschaft | Formulation of contrast media and process of preparation thereof |
WO2020108753A1 (en) | 2018-11-28 | 2020-06-04 | ITM Isotopen Technologien München AG | Novel tumor antigen binding agents and uses thereof |
CN113710286A (zh) * | 2019-02-14 | 2021-11-26 | 海德堡鲁普雷希特卡尔斯大学 | 具有改善的组织特异性的前列腺特异性膜抗原(psma)配体 |
US20220324898A1 (en) | 2019-02-14 | 2022-10-13 | Deutsches Krebsforschungszentrum | Prostate specific membrane antigen (psma) ligands comprising an amylase cleavable linker |
US20220125959A1 (en) * | 2019-04-26 | 2022-04-28 | Five Eleven Pharma Inc. | Prostate-specific membrane antigen (psma) inhibitors as diagnostic and radionuclide therapeutic agents |
AR119479A1 (es) | 2019-07-25 | 2021-12-22 | Bayer As | Radiofármacos dirigidos para diagnóstico y tratamiento de cáncer |
WO2021086917A1 (en) * | 2019-10-29 | 2021-05-06 | The Cleveland Clinic Foundation | Psma-targeting imaging agents |
WO2022096103A1 (en) | 2020-11-05 | 2022-05-12 | ITM Isotopen Technologien München AG | Combination of para-aminohippuric acid (pah) and radiolabeled complexes for treating cancer |
WO2022101352A1 (en) | 2020-11-12 | 2022-05-19 | Abx Advanced Biochemical Compounds Gmbh | Ligands of prostate specific membrane antigen (psma) containing heteroaromatic linker building blocks |
WO2022111800A1 (en) | 2020-11-25 | 2022-06-02 | Itm Solucin Gmbh | Stable formulations for radionuclide complexes |
AU2022210371A1 (en) | 2021-01-22 | 2023-07-20 | Bayer Aktiengesellschaft | Lrrc15 antibodies and conjugates thereof |
EP4355376A1 (en) * | 2021-06-17 | 2024-04-24 | Mayo Foundation for Medical Education and Research | Methods and materials for combining biologics with multiple chelators |
CN115745903A (zh) * | 2021-09-03 | 2023-03-07 | 晶核生物医药科技(南京)有限公司 | 一种肽脲素衍生物、含其的药物组合物及其应用 |
WO2023086833A1 (en) * | 2021-11-09 | 2023-05-19 | Case Western Reserve University | Psma targeted conjugate compounds and uses thereof |
WO2023208928A1 (en) | 2022-04-26 | 2023-11-02 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Dosage of psma-ligands for fluorescence based detection of cancerous tissue |
WO2023222680A1 (en) | 2022-05-17 | 2023-11-23 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Prostate specific membrane antigen (psma) ligands |
WO2023222682A1 (en) | 2022-05-17 | 2023-11-23 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Prostate specific membrane antigen (psma) ligands |
WO2023222679A1 (en) | 2022-05-17 | 2023-11-23 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Prostate specific membrane antigen (psma) ligands |
WO2023222681A1 (en) | 2022-05-17 | 2023-11-23 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Prostate specific membrane antigen (psma) ligands with improved renal clearance |
WO2023231452A1 (zh) * | 2023-02-14 | 2023-12-07 | 北京师范大学 | 含硝基芳香杂环基团的psma靶向放射性金属配合物及其制备 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003060523A1 (en) * | 2002-01-10 | 2003-07-24 | Johns Hopkins University | Imaging agents and methods of imaging naaladase of psma |
JP2010509358A (ja) * | 2006-11-08 | 2010-03-25 | バイオストリーム セラピューティクス インコーポレーティッド | グルタミン酸のヘテロダイマー |
WO2010065902A2 (en) * | 2008-12-05 | 2010-06-10 | Molecular Insight Pharmaceuticals, Inc. | Technetium- and rhenium-bis(heteroaryl) complexes and methods of use thereof for inhibiting psma |
WO2010108125A2 (en) * | 2009-03-19 | 2010-09-23 | The Johns Hopkins University | Psma-targeting compounds and uses thereof |
JP2010532754A (ja) * | 2007-06-26 | 2010-10-14 | ジョンズ ホプキンス ユニバーシティ | 前立腺特異膜抗原(psma)の標識阻害剤、生物学的評価およびイメージング剤としての使用 |
-
2012
- 2012-08-03 AU AU2012294639A patent/AU2012294639B2/en active Active
- 2012-08-03 EP EP12822647.9A patent/EP2739316B1/en active Active
- 2012-08-03 EP EP19155531.7A patent/EP3505192A1/en active Pending
- 2012-08-03 HU HUE12822647A patent/HUE045028T2/hu unknown
- 2012-08-03 PL PL12822647T patent/PL2739316T3/pl unknown
- 2012-08-03 CA CA2844151A patent/CA2844151C/en active Active
- 2012-08-03 WO PCT/US2012/049644 patent/WO2013022797A1/en unknown
- 2012-08-03 JP JP2014524142A patent/JP5843338B2/ja active Active
- 2012-08-03 ES ES12822647T patent/ES2732060T3/es active Active
- 2012-08-03 TR TR2019/10084T patent/TR201910084T4/tr unknown
- 2012-08-03 US US13/566,849 patent/US8926944B2/en active Active
-
2014
- 2014-11-25 US US14/553,157 patent/US9388144B2/en active Active
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003060523A1 (en) * | 2002-01-10 | 2003-07-24 | Johns Hopkins University | Imaging agents and methods of imaging naaladase of psma |
JP2010509358A (ja) * | 2006-11-08 | 2010-03-25 | バイオストリーム セラピューティクス インコーポレーティッド | グルタミン酸のヘテロダイマー |
JP2010532754A (ja) * | 2007-06-26 | 2010-10-14 | ジョンズ ホプキンス ユニバーシティ | 前立腺特異膜抗原(psma)の標識阻害剤、生物学的評価およびイメージング剤としての使用 |
WO2010065902A2 (en) * | 2008-12-05 | 2010-06-10 | Molecular Insight Pharmaceuticals, Inc. | Technetium- and rhenium-bis(heteroaryl) complexes and methods of use thereof for inhibiting psma |
WO2010108125A2 (en) * | 2009-03-19 | 2010-09-23 | The Johns Hopkins University | Psma-targeting compounds and uses thereof |
Cited By (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2021175743A (ja) * | 2015-09-21 | 2021-11-04 | ペドロ アナスタシオ セラノ−オヘダ | 癌を治療するためのグルタミン−高z元素化合物 |
JP2018529765A (ja) * | 2015-09-21 | 2018-10-11 | ペドロ アナスタシオ セラノ−オヘダ | 癌を治療するためのグルタミン−高z元素化合物 |
JP7266405B2 (ja) | 2015-09-21 | 2023-04-28 | ペドロ アナスタシオ セラノ-オヘダ | グルタミン-付着-高z元素化合物を含む放射線増感剤 |
JP2018537452A (ja) * | 2015-11-09 | 2018-12-20 | セルビオン カンパニー リミテッドCellbion Co,. Ltd | ペプチドチオ尿素誘導体、これを含有する放射線同位体標識化合物、およびこれを活性成分として含有する前立腺癌を処置または診断するための医薬組成物 |
JP2019519467A (ja) * | 2016-03-22 | 2019-07-11 | ザ・ジョンズ・ホプキンス・ユニバーシティ | 前立腺がんの内部放射線療法のための前立腺特異的膜抗原を標的とした高親和性薬剤 |
JP7073270B2 (ja) | 2016-03-22 | 2022-05-23 | ザ・ジョンズ・ホプキンス・ユニバーシティ | 前立腺がんの内部放射線療法のための前立腺特異的膜抗原を標的とした高親和性薬剤 |
JP2019527740A (ja) * | 2016-06-22 | 2019-10-03 | デクステック メディカル エービー | リジン−尿素−グルタメートファーマコフォアを含む修飾デキストラン複合体 |
JP2019535754A (ja) * | 2016-11-23 | 2019-12-12 | キャンサー ターゲテッド テクノロジー エルエルシー | アルブミン結合psma阻害剤 |
JP7167021B2 (ja) | 2016-11-23 | 2022-11-08 | キャンサー ターゲテッド テクノロジー エルエルシー | アルブミン結合psma阻害剤 |
JP2020516611A (ja) * | 2017-04-05 | 2020-06-11 | コーネル ユニバーシティー | 画像化および抗腫瘍治療において有用な調整可能な薬物動態を有する三官能性構築物 |
JP7396897B2 (ja) | 2017-04-05 | 2023-12-12 | コーネル ユニバーシティー | 画像化および抗腫瘍治療において有用な調整可能な薬物動態を有する三官能性構築物 |
JP2020522506A (ja) * | 2017-05-30 | 2020-07-30 | ザ・ジョンズ・ホプキンス・ユニバーシティ | 前立腺がんの内部放射線療法のための前立腺特異的膜抗原をターゲットとした高親和性薬剤 |
JP2020524175A (ja) * | 2017-06-19 | 2020-08-13 | フューチャーケム カンパニー リミテッドFuturechem Co.,Ltd. | 前立腺がんの診断のための18f標識化合物およびその使用 |
JP2021506784A (ja) * | 2017-12-13 | 2021-02-22 | サイエンコンス アクスイェ セルスカプ | 鉛またはトリウム放射性核種に連結されたpsma標的化化合物を含む錯体 |
JP7376481B2 (ja) | 2017-12-13 | 2023-11-08 | サイエンコンス アクスイェ セルスカプ | 鉛またはトリウム放射性核種に連結されたpsma標的化化合物を含む錯体 |
JP2021513542A (ja) * | 2018-02-06 | 2021-05-27 | ザ・ジョンズ・ホプキンス・ユニバーシティ | がん放射線治療法のための、psmaをターゲットとした放射性ハロゲン化した尿素‐ポリアミノカルボン酸塩 |
JP2021519822A (ja) * | 2018-03-30 | 2021-08-12 | フューチャーケム カンパニー リミテッドFuturechem Co.,Ltd. | 前立腺がんを診断および処置するためのpsma標的放射性医薬品 |
JP7094591B2 (ja) | 2018-03-30 | 2022-07-04 | フューチャーケム カンパニー リミテッド | 前立腺がんを診断および処置するためのpsma標的放射性医薬品 |
US11931431B2 (en) | 2018-03-30 | 2024-03-19 | Futurechem Co., Ltd | PSMA-targeted radiopharmaceutical for diagnosing and treating prostate cancer |
Also Published As
Publication number | Publication date |
---|---|
TR201910084T4 (tr) | 2019-08-21 |
EP2739316A1 (en) | 2014-06-11 |
AU2012294639B2 (en) | 2017-10-26 |
AU2012294639A8 (en) | 2014-03-06 |
CA2844151A1 (en) | 2013-02-14 |
WO2013022797A1 (en) | 2013-02-14 |
EP3505192A1 (en) | 2019-07-03 |
AU2012294639A1 (en) | 2014-02-27 |
PL2739316T3 (pl) | 2019-09-30 |
CA2844151C (en) | 2022-11-29 |
EP2739316B1 (en) | 2019-04-10 |
JP5843338B2 (ja) | 2016-01-13 |
US20130034494A1 (en) | 2013-02-07 |
HUE045028T2 (hu) | 2019-12-30 |
ES2732060T3 (es) | 2019-11-20 |
US8926944B2 (en) | 2015-01-06 |
EP2739316A4 (en) | 2015-03-11 |
US9388144B2 (en) | 2016-07-12 |
US20150078998A1 (en) | 2015-03-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5843338B2 (ja) | 放射標識された前立腺特異的膜抗原阻害剤 | |
JP6707677B2 (ja) | トリアジン系放射性医薬品及び放射線造影剤 | |
JP5220203B2 (ja) | テクネチウム−及びレニウム−ビス(ヘテロアリール)錯体及びpsmaを阻害するその使用方法 | |
JP7396897B2 (ja) | 画像化および抗腫瘍治療において有用な調整可能な薬物動態を有する三官能性構築物 | |
JP6275484B2 (ja) | Psma標的化デンドリマー |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20150609 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20150909 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20151013 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20151112 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5843338 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |